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1. Einleitung 
1.1 Tandem-Massenspektrometrie in der Klinischen Chemie 
Im methodisch-analytischen Spektrum der medizinischen Labordiagnostik besitzt die 
Quantifizierung von Marker-Substanzen in diagnostisch zugänglichen Untersuchungsmaterialien 
eine Schlüsselrolle; dies betrifft sowohl endogen vorkommende Substanzen wie auch Xenobiotica. 
Die gegenwärtig in der Routinediagnostik dominierenden Basis-Technologien sind die Photometrie 
und Liganden-Bindungsassays wie vor allem die Immunoassays. Die Einführung dieser 
Technologien in den 1960er bis 1980er-Jahren hat die medizinische Diagnostik revolutioniert, so 
dass Laboranalysen inzwischen für einen Großteil ärztlicher Entscheidungen von wesentlicher 
Bedeutung sind. Sowohl Photometrie- wie auch Immunoassay-basierte Analyseverfahren konnten 
mittlerweile komplett automatisiert werden, was zu einem sehr hohen Niveau an Effizienz und 
Zuverlässigkeit dieser klinisch-chemischen Basis-Technologien geführt hat. Gleichwohl weisen 
diese Analysensysteme wesentliche Limitierungen auf; dies betrifft die Analyt-Spezifität der Tests 
(z.B. kompetitive Immunoassays kleiner Moleküle wie Steroide), die Nachweisstärke (v.a. bei 
photometrischen Tests) und das realisierbare Analytspektrum.  
 Über die erwähnten Technologien der Routineanalytik hinaus verfügt die Klinische Chemie 
seit den 1980er Jahren über metrologisch höherrangige Referenzmethoden auf Basis der 
Gaschromatographie-Massenspektrometrie (GC-MS). Resultate dieser Technologie können – im 
Gegensatz zu Photometrie und Ligandenbindungs-Assays direkt auf die molekulare Struktur der 
Zielanalyten zurückgeführt werden, was einen sehr hohen Grad an analytischer Spezifität eröffnet. 
GC-MS-Methoden sind seit vielen Jahren von zentraler Bedeutung für die Standardisierung 
klinisch-chemischer Analysen, da z.B. Kalibrations- und Qualitätskontroll-Materialien sowie 
Ringversuchsproben hierdurch konsistent spezifiziert werden können. Darüber hinaus hat sich die 
GC-MS zu einer Schlüsseltechnik in der Toxikologie entwickelt, da sie die Identifikation von sehr 
vielen, auch primär nicht erwarteten Substanzen in diagnostischen Proben anhand von Spektren-
Bibliotheken erlaubt („unknown screening“); ebenso sind umfangreiche Multi-Analyt-
Quantfizierungen realisierbar. Höchste analytische Zuverlässigkeit kann durch die Verwendung von 
stabilisotopen-markierten internen Standards erreicht werden (Isotopenverdünnungs-Technik). 
Da das Handling der GC-MS außerordentlich anspruchsvoll und personalintensiv ist, konnte sich 
diese Technologie außerhalb von wenigen Speziallabors in der labormedizinischen Routineanalytik 
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allerdings nicht durchsetzen. 
 Ende der 1990er Jahre fand mit der Flüssigkeitschromatographie-Tandem-
Massenspektrometrie (syn. LC-MS/MS) eine weitere, innovative massenspektrometrische 
Technologie Einzug in die medizinische Analytik1,2. Diese Technologie teilt wichtige Potentiale mit 
der GC-MS (v.a. hohe Analyt-Spezifität, Anwendbarkeit der Isotopenverdünnungs-Technik, 
Multianalyt-Quantifizierung etc.), weist aber darüber hinaus wesentliche praktische Vorteile auf: 
 
- Im Gegensatz zur GC-MS erfordert die LC-MS/MS im Allgemeinen keine chemische 
Derivatisierung der Zielanalyten. 
- Da die Ionisation außerhalb des Hochvakuumbereichs erfolgt, ist die LC-MS/MS-
Technologie weitaus robuster. 
- Durch die Tandem-Anordnung zweier Massenselektoren (Quadrupole) mit 
zwischengeschalteter Kollisionszelle ist es möglich, die Analyt-Detektion auf das 
spezifische Fragmentationsverhalten zurückzuführen. Durch die hohe Spezifität dieses 
Detektionsprinzips kann die chromatographische Vor-Fraktionierung der Proben minimiert 
werden. Dadurch werden Multi-Analyt-Quantifizierungen mit sehr kurzen analytischen 
Laufzeiten möglich (z.B. Laufzeiten unter 3 min, gegenüber typischerweise 20 min bei der 
GC-MS).  
- Während die Anwendung der GC-MS auf thermostabile Analyte unterhalb eines 
Molekulargewichts von ca. 600 begrenzt ist, kann die LC-MS/MS alle biologisch relevanten 
Stoffklassen adressieren.  
 
 Die genannten Eigenschaften stellen für die gesamte Bioanalytik eine geradezu 
revolutionäre Novität dar. Bezüglich der Labormedizin eröffnet die LC-MS/MS die Perspektive, 
hoch-spezifische massenspektrometrische Verfahren nicht mehr nur in wenigen Speziallabors, 
sondern auch in Routinelabors einzusetzen. Um dieses Ziel, das zahlreiche konkrete Optionen für 
die Verbesserung der Patientenversorgung eröffnen kann, zu realisieren ist jedoch noch eine weitere 
Verbesserung der Anwenderfreundlichkeit gegenüber dem gegenwärtigen Stand erforderlich. Dies 
betrifft insbesondere die Probenvorbereitung. Da medizinisch-biologische Proben, wie Serum oder 
                                                 
1 Maurer HH. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal 
Bioanal Chem 2007;388:1315–25. 
2 Vogeser M, Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory--goals for further developments. 
 Clin Biochem 2008;41:649-62. 
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Urin eine extrem komplexe und stoffreiche Matrix darstellen, ist trotz der hohen analytischen 
Selektivität der Tandemmassenspektrometrie (MS/MS) -Technologie eine Vorfraktionierung der 
Probe erforderlich. Dabei gilt es insbesondere, Stoffe abzureichern, die die Ionisation der 
Zielanalyte beeinträchtigen. In der Analytik kleiner Moleküle betrifft dies vor allem Salze, Peptide 
und Proteine, sowie Phospholipide. Neben der Flüssigphasen-Extraktion mit organischen 
Lösungsmitteln wird hierfür häufig die Festphasenextraktion verwendet. Im klassischen Ansatz 
werden Extraktionskartuschen zur einmaligen Anwendung benutzt. Diese Verfahren sind 
materialaufwendig und bedingen eine hohe Personalbindung. Die Verwendung von permanent 
genutzten Extraktionssäulen hingegen ermöglicht eine weitgehende Automation der Festphasen-
Extraktion. Nach einer meist vorgeschalteten Proteinfällung wird über eine zweite HPLC-Pumpe 
sowie ein Hochdruckschaltventil eine Flußsystem realisiert, das die extraktiven Schritte Adsorption, 
Waschen und Elution in einem geschlossenen Flußschema realisiert (siehe Abbildung mit Legende). 
Da diese sogenannte on-line solid phase extration (SPE) die Probenvorbereitung von LC-MS/MS-
Analysen gegenüber Standardmethoden drastisch vereinfacht, ist sie für die Routineanwendung der 
LC-MS/MS von besonderem Interesse. 
 Die Technologie der on-line SPE verbessert nicht nur die Praktikabilität und 
Großserientauglichkeit der LC-MS/MS im klinischen Labor sondern kann auch die analytische 
Qualität optimieren: Eine weitgehende Reduktion von Begleitsubstanzen durch eine effiziente 
Extraktion führt im allgemeinen zu stabilen Ionisationsverhältnissen. Störungen der Ionisation 
(sogenannte ion-suppression) können die Richtigkeit von massenspektrometrischen Analysen 
beeinträchtigen sobald die Ionisation von Zielanalyt und Internem Standard differentiell beeinflusst 
werden. 
 
Die übergreifende Aufgabe des Promotionsprojektes bestand in der Entwicklung und Validierung 
neuer LC-MS/MS-Methoden für die klinisch-chemische Routinediagnostik. Hierbei wurde 
insbesondere der Aspekt der Probenvorbereitung adressiert, da dieser die Zuverlässigkeit und 
Praktikabilität der Verfahren ganz wesentlich determiniert. 
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Abbildung: Prinzip der on-line SPE (integriert in LC-MS/MS-Technologie), exemplarisch 
dargestellt an beschriebenen Methoden; aus Vogeser M, Kirchhoff F. Progress in automation of LC-
MS in laboratory medicine. Clin Biochem 2011;44:4-13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Beladung der SPE-Säule: Ein überwiegend wässriges Lösungsmittelgemisch transportiert 
Matrix und Substanzen auf die SPE-Säule. Dabei passieren polare Bestandteile die Säule 
ungehindert und werden in den Abfall gespült, unpolares Sorbens wird an der Säule reteniert 
(Abbildung 1, A). 
2. Elution des unpolaren Sorbens von der SPE-Säule: Durch ein überwiegend organisches 
Lösungsmittelgemisch werden die retenierten Sorbentien von der SPE-Säule gelöst. 
Anschließend erfolgen Chromatographie und Detektion im Massenspektrometer (Abbildung 
1, B). 
3. Rekonditionierung der SPE-Säule: Die SPE-Säule wird auf die nächste Injektion vorbereitet. 
Zunächst wird die Säule mit Hochorganik gereinigt und im Anschluss wieder mit den 
Startbedingungen äquilibriert (Abbildung 1, A). 
Für die on-line SPE werden zwei HPLC-Pumpen, darunter eine quartärnere Gradientenpumpe 
und ein 2-Positionen, 6-Port-Schaltventil benötigt. 
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1.2 Einzelne Publikationen 
1.2.1 Kirchhoff F, Lorenzl S, Vogeser M.  
 An on-line solid phase extraction procedure for the routine quantification of 
 urinary methylmalonic acid by liquid chromatography-tandem mass 
 spectrometry. 
 Clin Chem Lab Med 2010;48:1647-50.  
Vitamin B12- (Cobalamin-) Mangel ist ein relativ häufiger Befund, der durch die  
Serumcobalaminbestimmung als labordiagnostischer Primärtest diagnostiziert wird.3 Eine 
wesentlich höhere diagnostische Selektivität wird über die Quantifizierung von funktionellen 
Markermolekülen des Vitamin-B12Mangels - Methylmalonsäure bzw. Homocystein - erreicht. So 
kann als Goldstandard der Vitamin B12-Mangeldiagnostik die Bestimmung der Methylmalonsäure/ 
Kreatinin Ratio aus Spontanurin mittels LC-MS/MS gelten. 
Der Fokus der im Rahmen der Promotionsarbeit entwickelten und in o.g. Publikation beschriebenen 
Methode lag auf der Optimierung der Routinetauglichkeit der Urin-Methylmalonsäure-Messung 
mittels LC-MS/MS.  
Einer Flüssig/Flüssig-Extraktion mit anschließender Evaporation und Derivatisierung folgt eine on-
line SPE. Mittels HPLC wird die isobare und ubiquitär vorkommende Bernsteinäure von der 
Methylmalonsäure abgetrennt. Die abschließende Detektion erfolgt im Tandemmassenspektrometer. 
Validierungsdaten charakterisieren die Methode als robust und leistungsfähig.  
Im Vergleich zu bis dato publizierten Methoden konnte eine Verbesserung der Routinetauglichkeit 
durch Kompensation eines zweiten Evaporationsschritts durch die wesentlich schnellere on-line 
SPE erzielt werden . 
 
                                                 
3 Lechner K, Födinger M, Grisold W, Püspök A, Sillaber C.Vitamin B12-Mangel. Neue Daten zu einem alten Thema.Wien Klin Wochenschr 
2005;117/17: 579–591. 
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1.2.2  Kirchhoff F, Briegel J, Vogeser M.  
 Quantification of free serum cortisol based on equilibrium dialysis and isotope 
 dilution-liquid chromatography-tandem mass spectrometry.  
 Clin Biochem 2011;44:894-9.  
Die biologisch und analytisch akurate Charakterisierung der adrenocorticalen Funktionslage ist für 
eine Vielzahl medizinischer Fragestellungen von wesentlicher Bedeutung; dies gilt insbesondere für 
die Objektivierung von Stresseffekten und für die Intensivmedizin. Aufgrund der nicht-linearen 
Bindungscharakteristik von Cortisol mit dem Corticosteroidbindenden-Globulin (CBG) und 
individuell unterschiedlichen CBG-Konzentrationen, ist die Bestimmung des freien, nicht 
proteingebundenen Serum-Cortisols der Quantifizierung des totalen Cortisols überlegen. Da die 
FSC-Bestimmung grundsätzlich ein mehrschrittiges und komplexes Analyseverfahren darstellt, ist 
eine Referenzmethode erforderlich. An dieser sollen sich auch mögliche automatisierte 
Testverfahren orientieren. 
Für die Entwicklung einer gut praktikablen Kandidaten-Referenzmethode der freien Serum-Cortisol 
(FSC) Analytik wurde die Technik der Equilibrium-Dialyse zur Gewinnung des freien Cortisols aus 
Serum verwendet. Die Quantifizierung von Cortisol im Dialysat erfolgte mittels LC-MS/MS mit 
vorgeschalteter on-line SPE. 
Die neu entwickelte Methode erwies sich im Rahmen von umfangreichen Untersuchungen als 
robust und gut praktikabel.  
Aufbauend auf die in der Publikation dargestellte Entwicklungsarbeit kann in weiteren Projekten 
nun die Etablierung eines Referenzmeßsystems für den Analyten FSC angegangen werden. 
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1.2.3.  Kirchhoff F, Maier B, Rieger C, Ostermann H, Spöhrer U, Vogeser M.  
 An on-line solid phase extraction procedure for the routine quantification of 
 caspofungin by liquid chromatography-tandem mass spectrometry.  
 Clin Chem Lab Med 2012;50:521-4. 
Die Quantifizierung der systemischen Wirkkonzentration eines Arzneimittels zur Optimierung der 
Dosierung wird als Therapeutisches Drug Monitoring (TDM) bezeichnet.  
Eine TDM-Empfehlung für Medikamente kann nur auf einer ausreichenden Datenlage von 
klinischen Studien ausgesprochen werden. Voraussetzung hierfür sind genaue und präzise 
Quantifizierungsmethoden. 
Caspofungin, der im Klinikalltag am häufigsten zum Einsatz kommende Wirkstoff der neueren 
Generation aus der Gruppe der Echinocandine, wurde in der beschriebenen Methode adressiert. Die 
Methodenentwicklung orientierte sich an bis dato publizierten Arbeiten. Verbesserungen wurden in 
mehreren Punkten erzielt: Mit Tylosin, einem Wirkstoff aus der Veterinärmedizin, wurde ein 
kommerziell verfügbarer Interner Standard verwendet, der bedingt durch Co-Elution eine 
verlässliche Quantifizierung ermöglicht. Außerdem konnte der lineare Bereich, ein wichtiges 
Validierungskriterium, wesentlich erweitert werden. 
Durch den Einsatz von online SPE wurde eine verbesserte Routinetauglichkeit erzielt. Die LC-
MS/MS Methode kann für potentielles TDM und weitere klinische Studien zum Einsatz kommen.  
 
1.2.4  Vogeser M, Kirchhoff F.  
 Progress in automation of LC-MS in laboratory medicine.  
 Clin Biochem 2011;44:4-13. 
Eine Vielzahl von kleinen Molekülen kann mittels LC-MS/MS quantifiziert werden, was sie zu 
einer wertvollen Technologie für die Klinische Chemie macht. Wesentliche Limitierungen 
erschweren jedoch das Etablieren der Technologie im klinischen Routinelabor: Fachpersonal bleibt 
weiterhin bei Methodenimplementation und -anwendung unverzichtbar, die Robustheit der LC-
MS/MS – Systeme ist noch ungenügend und für den Routinebetrieb erforderliche automatisierte 
Anwendungen fehlen derzeit gänzlich. 
In unserer Übersichtsarbeit werden die bisherigen Ansätze zur Entwicklung gut praktikabler und 
voll routinetauglicher LC-MS/MS-basierter Analysensysteme für das klinische Routinelabor 
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systematisch aufgearbeitet und analysiert.  
Als wesentliches Fazit wird gezogen, dass die relevanten Einzelkomponenten für derartige Systeme 
bereits verfügbar sind, und die technisch-industrielle Umsetzung damit realisierbar erscheint. 
 
1.3 Zusammenfassung/ Summary 
Im Rahmen der Promotionsarbeit wurden LC-MS/MS Methoden für drei wichtige Analyte in den 
Bereichen der Ernährungsmedizin, Endokrinologie und dem Therapeutischen Drug Monitoring 
entwickelt.  Bei diesen Methoden konnte gegenüber bislang publizierten Methoden vor allem eine 
deutliche Verbesserung der Routinetauglichkeit erzielt werden. Dies gelang insbesondere durch den 
Einsatz einer semi-automatisierten Probenvorbereitung, der on-line SPE-Technologie. Der 
derzeitigen Stand der Automatisierung in LC-MS Laboren wurde zudem in einer Übersichtsarbeit 
analysiert und bewertet. Insgesamt wurden mit den Einzelarbeiten des Promotionsprojektes 
Beiträge zur Verbesserung der labormedizinischen Diagnostik durch Anwendung der innovativen 
Technologie LC-MS/MS geleistet. 
 
 
Within the period of the PhD work, LC-MS/MS method development was performed for three 
important analytes in the fields of nutritional medicine, endocrinology and therapeutic drug 
monitoring. Based on previously published methods, improvements concerning mainly the 
applicability for routine analyses were achieved, particularly by semi-automated sample preparation 
protocols – applying on-line solid phase extraction prior to LC-MS/MS. Moreover, current 
characteristics of automatisation in LC-MS laboratories were analysed in a review.  
Application of the innovative technology LC-MS/MS in the published studies makes a substantial 
contribution to diagnostics in laboratory medicine. 
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2. Originalpublikationen 
2.1 Kirchhoff F, Lorenzl S, Vogeser M.  
 An on-line solid phase extraction procedure for the routine quantification of 
 urinary methylmalonic acid by liquid chromatography-tandem mass 
 spectrometry.          
 Clin Chem Lab Med 2010;48:1647-50.     
 
 
 
 
 
 
 
 
 
 
 
 
Seite 9
Clin Chem Lab Med 2010;48(11):1647–1650  2010 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2010.310
2010/687
Article in press - uncorrected proof
Short Communication
An on-line solid phase extraction procedure for the routine
quantification of urinary methylmalonic acid by liquid
chromatography-tandem mass spectrometry
Fabian Kirchhoff1,*, Stephan Lorenzl2 and
Michael Vogeser1
1 Institute of Clinical Chemistry, Hospital of the University
of Munich, Munich, Germany
2 Clinic of Neurology, Hospital of the University of
Munich, Munich, Germany
Abstract
Background: The goal of this study was to develop and to
validate an improved isotope-dilution-liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS) method for the
quantification of methylmalonic acid (MMA) in urine.
Methods: A previously described sample preparation pro-
tocol requires two solvent extraction steps, including evap-
oration. The first extraction is to extract the analyte from the
sample, and second occurs following derivatization of the
extract. In the method described here, the second evaporation
step was substituted by on-line solid phase extraction
employing column-switching and a permanent co-polymer
based extraction cartridge. A standard validation protocol
was applied to investigate the performance of the method.
Results: The method was found to be linear in the clinically
relevant range of concentrations (6–100 mmol/L). Total coef-
ficients of variation were below 10% and inaccuracy was
-10% for quality control samples at three concentrations.
Conclusions: By omitting one evaporation step, the semi-
automated method described in this article enables for more
convenient work-flow in the quantification of urinary MMA
compared to the previous protocol. This is of relevance for
MMA measurement in the routine clinical laboratory setting.
Validation demonstrated acceptable analytical performance.
Clin Chem Lab Med 2010;48:1647–50.
Keywords: liquid chromatography-tandem mass spectro-
metry (LC-MS/MS); methylmalonic acid (MMA); on-line
solid phase extraction (SPE); urine.
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Phone: q49 89 7095 3248, Fax: q49 89 7095 6220,
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Received December 23, 2009; accepted May 21, 2010;
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Increased concentrations of methylmalonic acid (MMA) are
recognized as a useful tool for the detection of cobalamin
(vitamin B12) deficiency at the tissue level (1–3). Whereas
serum cobalamin concentrations can be determined using
high throughput ligand binding methods, reliable quantifi-
cation of MMA in biological matrices requires the use of
mass spectrometric methods. Since the degree of automation
in mass spectrometric assays is limited (4), MMA quantifi-
cation is not used at present for screening of cobalamin defi-
ciency. Rather, it is typically used as a confirmatory second
line test in cases where vitamin B12 concentrations are
below 300 pg/mL.
The assessment of MMA concentrations in serum is ham-
pered by the fact that a decreased glomerular filtration rate
is associated with increased serum MMA concentrations,
irrespective of the cobalamin status (5, 6). In contrast, quan-
tification of the urinary MMA/creatinine-ratio is not subject
to interference by impaired renal function, and is thus supe-
rior to serum MMA measurements (7). Furthermore, urine
MMA concentrations are about 100-fold higher compared to
serum, which favours the robustness of analytical methods
for urine as the sample material (reference ranges (8): serum
MMA, -0.44 mmol/L wconversion of units for methylma-
lonic acid: (mmol/L)=0.118s(mg/L)x; urinary MMA/
creatinine-ratio, -3.56 mmol/mol; assuming a typical mean
urinary creatinine concentration of roughly 8.5 mmol/L, uri-
nary MMA concentrations -30 mmol/L can be considered
normal).
Gas chromatography-mass spectrometry (GC-MS) meth-
ods for the quantification of urinary MMA were introduced
in the late 1970s (9). To date, two liquid chromatography-
tandem mass spectrometry (LC-MS/MS) methods for quan-
tification of urinary MMA have been described (10, 11). Due
to the highly-specific detection principle, the need for time
consuming chromatographic separation is, in general, mini-
mized in LC-MS/MS and many laboratories are now trying
to switch MMA quantification from GC-MS to LC-MS/MS.
The methods that have been described for quantification
of urinary MMA using LC-MS/MS include a multi-step
sample preparation protocol. While the method described by
Magera et al. (11) uses solid phase extraction, the method
by Kushnir et al. (10) employs the more economic principle
of solvent extraction. This protocol includes a solvent extrac-
tion step with evaporation of the extracts both before and
after the derivatization step. The aim of our work was to
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Figure 1 (A) Scheme of the on-line solid phase extraction system (AC, analytical column; W, waste; MS, mass spectrometry system).
(B) Representative MRM chromatograms obtained from a normal urine sample (MMA 9.3 mmol/L). Upper panel: dibutyl-d3-MMA. Lower
panel: dibutyl-MMA (retention time approx. 4.9 min) base-line separated from dibutyl-SA (retention time approx. 4.3 min).
Sample preparation protocol: Into 1.5 mL polypropylene cups, 50 mL of calibrator, quality control samples or human urine samples was
mixed with 50 mL of d3-MMA (8.32 mmol/L) and 25 mL of 1 M HCl. After equilibration, 1600 mL methyl tertiary butyl ether (MTBE)
was added and the cups were shaken for 10 min using a horizontal shaker. After stopping the shaking, a complete separation between
aqueous and organic phase was obtained within seconds without centrifugation, with the organic layer above the aqueous phase. The organic
phase was transferred into a 2.0 mL polypropylene cup, which was then placed into an evaporation device, thermostated at 378C (Barkey
Vapotherm, Labortechnik Barkey, Leopoldsheim, Germany). The extract was evaporated to dryness under a flow of nitrogen. The residue
was dissolved in 50 mL of the derivatization reagent 3 N HCl/BuOH by vortex mixing. The cups were opened and placed uncapped into
a derivatization oven which was housed in a hood. Derivatization was performed at 708C for 30 min. Subsequently, 300 mL AcN/H2O (75/
25 by volume) was added to the tubes. After mixing, 100 mL of this solution were transferred into HPLC vials. On-line solid phase
extraction protocol: A Waters Oasis HLB column (25 mm, 2.1=20 mm, stationary phase: specific ratio of two monomers, hydrophilic N-
vinylpyrrolidone and lipophilic divinylbenzene; Waters, Milford, USA) was used. First 30 mL of derivatized sample extract was injected
and loaded onto the extraction column in valve position A. The mobile phase was water/methanol 90/10 (v/v), delivered at a flow rate of
4 mL/min. Potentially interfering compounds were washed into waste. In parallel, the analytical column (Waters xBridge Shield RP18,
2.1=150 mm; 3.5 mm particle size) was equilibrated with 1 g/L formic acid-acetonitrile/10 mM ammonium formiate 60/40 (v/v), delivered
at a flow rate of 0.4 mL/min. After 1 min, the switching valve was changed to position B; the extraction column was now eluted in a back-
flush mode onto the analytical column. After another 2 min, the valve was switched back to position A. During the analytical chromatography
into the mass spectrometer in position A, the extraction column was washed with acetonitrile/methanol 50/50 (v/v) at a flow rate of 4 mL/
min for 1 min and the extraction column subsequently re-equilibrated with water/methanol 90/10 (v/v). The analytical column was kept at
388C in a column oven, while the extraction column was kept at ambient temperature.
improve this previously reported process of sample prepa-
ration for quantification of urinary MMA using LC-MS/MS
by applying on-line solid phase extraction (SPE) with a
permanent extraction cartridge (a scheme of the on-line SPE
procedure is shown in Figure 1A).
We used a Waters Alliance 2795 HPLC module (Waters,
Milford, MA, USA), coupled splitless to a Micromass Quat-
tro LC tandem mass spectrometry system (Waters, Manches-
ter, UK). For on-line solid phase extraction, a SPE column
was used, together with a six-port high-pressure switching
valve. Mass spectrometric conditions are listed in the online
data supplement, Appendix 1.
Calibrators were made by diluting a stock solution of
MMA with water to obtain MMA concentrations of 101.6,
76.2, 50.8, 38.1, 25.4, 12.7, 6.4 mmol/L. We used three lev-
els of quality control samples, prepared by spiking pooled
urine from healthy volunteers. Before spiking, the MMA
concentration of this pool was determined by an independent
GC-MS method, with cross-validation by an external labo-
ratory. Target concentrations of the three quality control sam-
ples were calculated from the concentration of the pool and
from the amount of spiked MMA. Aliquots of the quality
control samples, as well as calibrators were stored at –208C.
Two urine pools were prepared for additional validation of
reproducibility in the use of the method in an epidemiolog-
ical study.
The complete sample preparation and on-line SPE proce-
dure is provided in the legend to Figure 1. The retention time
of dibutyl-MMA and the internal standard dibutyl-d3-MMA
was approximately 4.9 min after injection onto the extraction
column. The total analytical run time was 6.5 min. For quan-
tification, the peak area-ratios of the multiple reaction mon-
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Table 1 Results of the method validation study (four-fold determination of spiked quality control samples in four analytical series).
Target Found Mean Total coefficient Intra-assay
concentration, concentration accuracy of variation coefficient
mmol/L (mean), mmol/L (ns16 in (ns16 in of variation
4 series), % 4 series), % (ns4; range)
QC level 1 29.4 28.9 –2.0 8.2 5.3%–11.6%
QC level 2 80.2 73.2 –8.7 5.5 2.3%–6.7%
QC level 3 173 159 –8.3 6.0 3.0%–6.6%
itoring (MRM) trace of dibutyl-MMA and the internal
standard dibutyl-d3-MMA were assessed. No fit weighting or
axis transformation was applied.
An essential characteristic of quantification of MMA by
LC-MS/MS is the need to obtain specificity towards succinic
acid (SA) – which is isobaric with MMA and occurs natu-
rally. While Kushnir et al. report that these isobaric com-
pounds are distinguishable based on different fragmentation
patterns, we were not able to obtain differentiation by MS/
MS. Consequently, baseline chromatographic separation of
MMA from SA is required for reliable quantification of uri-
nary MMA (molecular structures of MMA, SA and d3-MMA
are shown in the data Supplement Figure 1). To verify com-
plete chromatographic separation of dibutyl-MMA from
dibutyl-SA, we analyzed pure solutions of the respective
compounds as well as a mixture of both. We were able to
demonstrate baseline separation and a representative MRM-
chromatogram is shown in Figure 1B.
To test the efficacy of the on-line solid phase extraction
protocol, derivatized samples were injected directly onto the
analytical column, and for comparison, onto the entire ana-
lytical system including the on-line solid phase extraction.
This was performed in triplicate for the three quality control
samples. We observed approximately 30% higher MRM peak
areas in the MRM trace of dibutyl-d3-MMA when applying
on-line SPE compared to direct injection of the extracts
(mean peak area of the QC samples without on-line SPE,
986 and using on-line SPE, 1271).
To study the recovery of the method, five urine samples
were spiked with a pure solution of MMA (50 mL sample
was spiked with 50 mL of a 101.6 mmol/L MMA solution)
prior to sample preparation. Comparative analyses of spiked
vs. unspiked samples demonstrated a mean recovery rate of
95.4% (range: 91.8%–97.9%).
In order to characterize the sensitivity of the analytical
system, a MMA solution with a concentration of 3.2 mmol/L
was analyzed in triplicate. A mean signal-to-noise ratio of
36:1 was found.
Ion-suppression characteristics of the method were
assessed by connecting a T-piece between the chromato-
graphic column and the ion source. Using a syringe pump,
a pure solution of dibutyl-MMA (12.7 mmol/L) was deliv-
ered at a constant flow rate (0.2 mL/min) into the T-piece.
With this post-column infusion, a baseline offset was
generated in the MRM-trace of dibutyl-MMA. We did not
observe any significant variation of this offset upon injection
of human urine samples, ruling out relevant ion suppression
by residual matrix components.
Potential carry over was excluded by injecting extracts
from the highest quality control sample in quadruplicate,
immediately followed by injection of a blank sample. The
chromatogram for this sample showed no peaks in the MRM
trace of dibutyl-MMA.
In four analytical series, applying full calibration, the
mean observed results of the three quality control samples
were compared with the expected concentrations and accu-
racy was calculated. We demonstrated mean accuracy and
coefficients of variation below 10% (Table 1). Furthermore,
we found that the coefficient of determination of the seven
calibrator samples was )0.99 in all series.
In addition, inter-assay coefficients of variation were cal-
culated for two different quality control samples which were
analyzed over a six week period in 14 series for application
of the method in an epidemiological study. These two pool
samples showed a coefficient of variation of 8.2% (mean
concentration 5.3 mmol/L) and 5.2% (mean concentration
20.0 mmol/L).
Apart from several articles which describe analysis of
underivatized MMA by LC-MS/MS using electrospray ioni-
sation in the negative mode (12, 13), the majority of pub-
lished work uses the positive mode. This may be attributed
to a rather low ion yield, using negative ionization in many
instruments including ours. In order to use the positive ioni-
sation mode, derivatization of MMA to dibutyl-MMA is
required. SPE is used in the method presented here, primarily
to protect the ion source from the aggressive derivatization
mixture and second, in order to avoid the second evaporation
step which was applied by Kushnir et al. (10) following the
derivatization step. Our modified sample preparation proto-
col realizes a time saving of more than 1 h for a batch of 50
samples when compared to the method described by Kushnir
et al.
We confirmed close agreement between the method
described here and the method described by Kushnir et al.
Ten samples analyzed by both methods showed a mean devi-
ation of 2.2%; range: –9.6% to q11.0%.
The additional analytical run time required for the auxil-
iary on-line SPE sample clean-up step is moderate with
1 min (or approx. 15% of the run-time); only one additional
isocratic pump and a switching valve is required. According
to our extensive experience with quantification of immuno-
suppressants (14), on line SPE columns made of multifunc-
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tional co-polymer are very robust and can be used for several
thousand injections.
The results of the method validation study (sensitivity, ion
suppression effects, carry over, as well as imprecision and
accuracy), qualify the assay described here as being suitable
for routine clinical application. However, when considering
that the method incorporates isotope-dilution internal stan-
dardisation, coefficients of variation above 5% are surpris-
ing; which is in qualitative agreement with previous studies
(10, 11). It may be assumed that isotope effects involved in
the processes of derivatization, ionisation, and/or fragmen-
tation could account for this observation. It has been shown
previously that LC-MS/MS may be more prone to isotope
effects than that observed in GC-MS (15).
The method was found to be convenient and robust with
the approach of on-line SPE employing column switching in
a large scale application: analysis of several hundred samples
did not lead to any visible spoiling of the ion source com-
ponents and no loss in sensitivity.
In summary, based on our results and experience, we can
recommend the improved protocol described here. Our pro-
tocol involves the first on line SPE, and omits one evapo-
ration step for the quantification of urinary MMA in the
routine clinical laboratory setting.
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Objectives: Only unbound serum cortisol is bioactive and protein binding of cortisol is highly variable. Thus,
the quantification of free serum cortisol (FSC) is of superior biological relevance compared to total serum
cortisol quantification. Consequently, the development of automated routine tests for FSC for endocrine
testing is desirable— along the lines of free thyroid hormone measurement. Since the availability of a reliable
and matrix-independent method is an important tool for this goal, we have developed a highly standardised
mass spectrometric FSC method.
Design and methods: We used equilibrium dialysis (ED) to obtain a protein-free fraction from serum
samples. The cortisol content of the dialysate was quantified using isotope-dilution two dimensional liquid
chromatography (LCxLC–MS/MS).
Results: Comprehensive evaluation characterised the method as reliable and robust; using commercially
available dialysis cells, convenient handling was realised.
Conclusions: The method described in this article can be suggested for the implementation of a reference
measurement system for FSC.
© 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Introduction
Quantification of cortisol in serum is a cornerstone in the diagnostic
work-up of patients with suspected abnormalities in adrenocortical
function, such as Cushing's disease or Addison's disease, but also in
patients at risk for critical illness-related corticosteroid insufficiency
[1]. Several automated immunoassays are available for routine
quantification of total serum cortisol (TSC) concentrations. Under
normal conditions more than 90% of circulating cortisol in human
serum is bound to proteins, mainly to corticosteroid-binding globulin
(CBG) and to a minor proportion to albumin and to erythrocytes [2].
Since cortisol can interactwith its intracellular receptors only after free
diffusion through cell membranes, merely the unbound fraction of
cortisol (free serum cortisol, FSC) is considered to be bioactive.
The protein binding of serum cortisol is highly variable due to non-
linear molecular binding characteristics and due to very substantial
inter- and intra-individual variation in CBG concentrations. During
acute illness, CBG is cleaved and concentrations decrease profoundly; FSC, free serum cortisol; TSC,
ltrafiltration; ERM, European
chromatography; IS, internal
tion; MRM, multiple reaction
mistry, University of Munich,
+49 89 7095 6220.
n.de (F. Kirchhoff).
ociety of Clinical Chemists. Publish[3]; if the molar concentration of TSC exceeds themolar concentration
of CBG, the bio-availability of cortisol increases dramatically due to
spill-over [4]. Several xenobiotics, such as synthetic estrogens, in
contrast, induce hepatic CBG synthesis resulting in decreased
bioavailability of cortisol. For these reasons, quantification of FSC is
considered to be biologically far more meaningful compared to TSC
quantification in the context of endocrinological in vitro-diagnostics.
Therefore, it is desirable that routine tests for FSCwill be developed by
the diagnostic industry, along the lines of free thyroid hormone
testing. Notably, the biological variability of cortisol protein binding is
much more pronounced compared to thyroxin.
FSC can be estimated mathematically from TSC and CBG concentra-
tions, either by simple division (FSC index [5]) or by applying formulas,
described by Coolens et al. [6] or by Dorin et al. [7]. Both equations
incorporate the typical binding characteristics between cortisol and
CBG. This approach has several shortcomings: CBG quantification by
radioimmunoassay is time consuming and not standardised; individual
variability in CBG binding properties – e.g. determined by competing
steroids, free fatty acids, drugs or potentially alsodisease-related – is not
considered. Moreover the contribution of cortisol binding to albumin is
either estimated and simplified in the formula [6] or albumin
quantification is required [7]. Furthermore, calculated results are
biassed by the cumulative total error of two or three distinct tests.
Future routine FSC tests will most likely relay on immunoassays by
omitting the analyte-release step which is included in the assay
protocol of total hormone tests — as applies for free thyroid hormoneed by Elsevier Inc. All rights reserved.
Fig. 1. Molecular structure of A) cortisol and B) d3-cortisol.
895F. Kirchhoff et al. / Clinical Biochemistry 44 (2011) 894–899assays. However, it has to be objectified during the development of
such one-step routine tests, that protein binding is entirely unaffected
by the assay protocol and that matrix effects are controlled. Thus, for
the development of such routine FSC tests, the availability of a reliable
matrix independent comparison method is crucial. The aim of our
project was to develop a respective mass spectrometry based method.
Free hormone reference assays are typically based on obtaining a
protein free preparation from a serum or plasma sample aliquot in
which the target analyte is quantified subsequently. This can be
achieved by ultrafiltration (UF) using filter devices with a defined
molecular cut-off, ranging between the molecular weight of the
hormone analyte and its binding protein [8–10]. This approach is
hampered by potential protein concentration effects on the filter layer
and a cumbersome handling of UF devices. Alternatively, equilibrium
dialysis (ED) can be used. This technique is time consuming but
probably less prone to artefacts and easy to handle if commercial
dialysis cells are used. Once a binding-protein-free preparation is
obtained from serum, reliable quantification of cortisol ideally
involves a mass spectrometric method based on the principle of
isotope dilution (ID) internal standardisation. Gas chromatography–
mass spectrometry may be applied for this aim; however, liquid
chromatography–tandem mass spectrometry (LC–MS/MS) is now
more widely available and is much more convenient, since no
derivatisation is required. Based on these considerations, we decided
to employ ED and ID-LC–MS/MS for the development of a working
reference assay for the quantification of FSC. In particular we aimed to
investigate whether a standard LC–MS/MS instrument is applicable in
this context with respect to analytical sensitivity. In this manuscript a
method is described in detail and results of a comprehensive
evaluation study are given.Fig. 2. Rapid Equilibrium Dialysis (RED) Device from Thermo Scientific. Single ED-units
(highlighted in the picture) are inserted into a reusable base plate. Removing of used
cells with an extraction tool is shown.Materials and methods
We obtained methanol and water, both HPLC gradient grade, from
Baker (Deventer, The Netherlands). Ammonium formate was from
Sigma-Aldrich (Steinheim, Germany); a stock solution (500 mM) was
made in water. NaCl, KCl, Urea, NaN3, ZnSO4∙7H2O and NaOH were all
obtained from Merck (Darmstadt, Germany); Na3PO4∙12H2O,
MgSO4∙7H2O, HEPES (free acid), and CaCl2∙2H2O were from Sigma-
Aldrich. All compounds were of the highest purity available.
Cortisol as a pure compound (98.7% purity by HPLC; Vetranal®)
was purchased from Sigma-Aldrich. Threefold deuterated cortisol (d3-
cortisol), used as the internal standard (IS), was purchased from
Cambridge Isotope Laboratories (Andover, USA). Molecular structures
of the compounds are shown in Fig. 1.
We prepared stock solutions of cortisol (500.9 mg/L) and d3-cortisol
(17.3 mg/L) in methanol in 10 ml volumetric flasks made of glass. A
50 μg/L cortisol working solution was prepared in protein-free buffer
(see next paragraph). An IS working solution, containing 200 μg/L d3-
cortisol was prepared in MeOH/ZnSO4∙7H2O (4/1 by volume).
A 200 ml working solution of the protein-free buffer (dialysis
buffer) was prepared according to Yue et al. [11]. In brief, for 200 ml
dialysis buffer NaCl (1.038 g), Na3PO4∙12H2O (0.25 g, which is
equivalent to 0.1 g Na3PO4), KCl (0.0646 g), MgSO4∙7H2O (0.0492 g),
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
(7.44 g), Urea (0.06 g), CaCl2∙2H2O (0.055 g), NaN3 (0.104 g) was
dissolved in 200 ml of gradient grade water. The pH was adjusted to
7.28±0.01 using 2.0 M NaOH at 22 °C.
We purchasedRapid EquilibriumDialysis (RED)Device Inserts and a
reusable base plate from Thermo Scientific Inc. (Pierce Biotechnology,
Thermo Scientific, Waltham, USA). Fig. 2 illustrates the application of
these devices. The base plate has a standard 96-well MTP footprint.
Dialysis device inserts consist of a buffer chamber and of a sample
chamber, separated from each other by a vertical cylinder membrane
with a molecular weight cut-off of approximately 8000 Da. TheseSeite 16devices are inserted into the base plate and extracted after use with a
special tool.
Experimental
Investigation of the ED variables
The manufacturer of the ED devices provides a pre-use washing
protocol which might be useful for some of the potential analytes
(soaking of the inserts for 10 min in ultra-pure water). In order to
investigate if this washing/preconditioning step is necessary in case of
FSC, we compared results found for patients' samples using pre-
washed and not pre-washed devices. Randomly selected leftover
serum (n=6) was used for this experiment. Close agreement was
found and consequently no washing step was applied in the future
study.
Fig. 3. Scheme of the on-line solid phase extraction system used in the quantification of
cortisol in dialysate (AC, analytical column; W, waste; MS, mass spectrometry system).
Position A, injection and adsorption of analytes to the extraction column; position B,
elution of the analytes from the extraction column onto the analytical column and the
mass spectrometer.
896 F. Kirchhoff et al. / Clinical Biochemistry 44 (2011) 894–899We furthermore evaluated the ratio of serum to dialysis buffer. For
this aim, volumes of spiked buffer of 400, 500 and 600 μL, respectively,
were dialysed against 600 μL of buffer. Four different concentrations
were analysed in duplicate. Contrary to suggestions from Thermo
Scientific (recommending a sample to buffer ratio from 1:1.5–3), in
our experiments only the 1:1 volume ratio resulted in complete
equilibration.
Subsequently, we tested if the volume of serum and dialysis buffer
has an impact on results. Serum volumes of 400, 500 and 600 μL,
respectively, were dialysed against the same volume of buffer (n=6).
FSC results obtained were compared. We did not observe an impact of
the fluid volume on results.
To investigate the dialysis time required, pool serum was
submitted to analysis in separate devices for 3, 4, 6, 7, 8, 10, 12, 14
and 16 h, and FSC was determined. This experiment was done in
duplicate. Cortisol concentrations in dialysate increased from 3 to 10 h
of dialysis and remained constant thereafter.
Based on these experiments (and applying the quantification
protocol described below) analyses were standardised to the
following conditions: Aliquots of 400 μL serum samples were dialysed
against 400 μL dialysis buffer at 37±0.2 °C for 16 h with constant
horizontal shaking of 100 rpm at ambient air. The base plate was
covered with aluminium foil and additionally fixed with sealing tape.
We discarded the single-use inserts and washed the reusable base
plate as recommended by Thermo Scientific for the next application.
Calibration and quality control materials
Calibrators were made by diluting the working solution of cortisol
with dialysis buffer to obtain cortisol concentrations of 50.0, 25.0,
12.5, 6.3, 3.1, 1.6, and 0.8 μg/L. Additionally, dialysis buffer was used as
blank-sample and zero-calibrator. Aliquots of the calibrators were
stored in polypropylene vials at −80 °C.
Quality control samples in three concentration levels were made by
spikingdialysis buffer to 45.1, 15.0 and 1.0 μg/L of cortisol. For this aim, a
cortisol stock solution was separately weighted in; aliquots of the
quality control samples were stored in polypropylene vials at −80 °C.
An aliquot of European Reference Material ERM-DA192 (cortisol in
human serum(unspiked))wasobtained fromLGCStandards (Midlesex,
England; specified total cortisol concentration 98.8±2.0 μg/L).
Three serum pools were prepared to study the imprecision of the
method. We used two distinct blood collections from one healthy
volunteer. The first sample was taken at 11 p.m., in order to
characterise a low cortisol concentration range, whereas the second
sample was taken at 8 a.m., characterising physiological high serum
cortisol concentrations. The third serum pool was prepared from
residual serum send for standard clinical chemistry analyses from
several intensive care unit patients. The pools were aliquoted in
polypropylene vials and stored at −80 °C.
Post-ED sample preparation
After dialysis, 150 μL of dialysate was transferred into 1.5 ml
polypropylene cups; the same applied for calibration and quality
control samples, whichwere not submitted to ED. Subsequently, 50 μL
of IS working solution was added to the samples. The cups were
vortexed and then shaken for 10 min using a horizontal shaker. This
was followed by centrifugation for 10 min at 21,470 rcf. Supernatant
was transferred into HPLC vials.
Instruments
A Waters Alliance 2695 HPLC module (Waters, Milford, USA) was
used, together with a second isocratic HPLC pump (CLC300;
Chromsystems, Munich, Germany) in the on-line solid phase
extraction (SPE) configuration described below. A Micromass QuattroSeite 17LC tandem mass spectrometry system (Waters, Manchester, UK) was
used for analyte detection. The chromatographic system was coupled
splitless with the MS-system.
Chromatography
On-line solid phase extraction was used for sample clean up in a
two dimensional liquid chromatography (LCxLC) set-up. For this aim,
a Waters Oasis HLB column (2.1×20 mm; 25 μm particle size, Waters,
Milford, USA) was used together with a six-port high-pressure
switching valve (Rheodyne, Rohnert Park, CA, USA) which was
controlled by the Micromass MassLynx 4.0 mass spectrometry
software. The automated extraction procedure consisted of three
steps. First 50 μL of the supernatant was injected and loaded onto the
extraction column in valve position A (Fig. 3). The mobile phase was
water/methanol 90/10 (v/v), delivered at a flow rate of 4 mL/min.
Potential interfering compounds were washed into waste. In parallel,
the analytical column (Kinetex C-18, 2.1×100 mm; 2.6 μm particle
size; Phenomenex, Torrance, USA) was equilibrated with 80/20 (v/v)
methanol/40 mM ammonium formate, delivered at a flow rate of
0.2 mL/min. After 1 min, the switching valve was changed to position
B; the extraction column was now eluted in a back-flush mode onto
the analytical column. After another 2 min, the valve was switched
back to position A. During the analytical chromatography into the
mass spectrometer in position A, the extraction column was washed
with pure methanol at a flow rate of 4 mL/min for 1 min and the
extraction column was subsequently re-equilibrated with water/
methanol 85/15 (v/v). The analytical column was kept at 40 °C in a
column oven, while the extraction column was kept at ambient
temperature.
The retention time of cortisol and d3-cortisol was ~2.8 min after
injection onto the extraction column. The total analytical run-time
was 4.0 min. For quantification, the peak area-ratios of the multiple-
reactionmonitoring (MRM) trace of cortisol and the internal standard
d3-cortisol were assessed. No fit weighting or axis transformation was
applied.
Mass spectrometric conditions
Electrospray ionisation in the positive mode was used. Source
parameters were tuned to obtain the protonated quasi-molecular ions
of cortisol and d3-cortisol, respectively (363 and 366 m/z). The
following settings resulted in optimal ion yield: capillary voltage,
2.45 kV; cone voltage, 35 V; source temperature, 120 °C; desolvation
temperature, 350 °C; nitrogen flow, ~700 L/h; cone gas flow, ~140 L/h.
The collision energy with argon as the collision gas was 20 V. For
897F. Kirchhoff et al. / Clinical Biochemistry 44 (2011) 894–899quantification the following MRM transitions were recorded: cortisol,
363N121; d3-cortisol 366N121. The dwell time for the MRM traces for
cortisol and d3-cortisol, respectively, was 0.2 s.
A representative chromatogram acquired from a serum sample
dialysate is given in Fig. 4.
Assay validation
Reproducibility, accuracy and linearity of the method were
validated in 12 analytical series over a period of 20 weeks applying
full calibration. The matrix-free spiked quality control samples at
three concentrations were analysedwithout the dialysis step in three-
fold determination within these series in order to determine accuracy
of the quantification part of the method. Imprecision of the entire
method (including ED) was studied by analysing the three serum
pools in each run applying the entire protocol. For calculation of the
intra-assay coefficient of variation, 10 aliquots of each pool were
analysed in one series.
To study the recovery of the quantification method, pool serum
samples were spiked with different amounts of the cortisol working
solution inorder toobtain threedifferent concentration levels (+5,+10
and +20 μg/L cortisol). Comparative TSC analyses of spiked versus
unspiked samples were evaluated in duplicate in one run (n=6).
To determine the sensitivity of the quantification method (lower
limit of quantification, LLOQ), we analysed spiked dialysis buffer in
duplicate in three runs (concentration of cortisol, 0.1, 0.2, 0.4 μg/L); to
investigate the upper limit of quantification (ULOQ) we prepared
samples with cortisol concentrations of 400, 450 and 500 μg/L,
respectively. Deviation of ±20% from the target concentrations was
defined as the criterion for acceptance.
Lyophilized serum cortisol reference material ERM-DA192 was
reconstituted in water. Subsequently, aliquots were analysed for total
cortisol concentrations not applying the ED procedure in order to
proof accuracy of the method with reference to an international
standard preparation. Moreover we quantified FSC of ERM-DA 192 in
triplicate in order to allow comparison of the results if the assay is
implemented on a different site.
With respect to the selectivity of the method, two databases (NIST
Mass spectral database; Metlin Metabolite Database) were searched
for compounds with similar molecular weight (±2 Da) as cortisol or
d3-cortisol. 4 compounds were found to be potentially relevant. In
order to exclude interference by isobaric compounds in patients'
samples, extended chromatography was applied in pool samples
(column: Lichrospher 100 C-18, 250×4 mm; 5 μm particle size; flow
0.7 ml/min, split approximately 1:3). MRM traces were inspected for
peakswith retention times differing from that of cortisol andd3-cortisol.
The retention time of cortisol was 5.3 min in this chromatographic
configuration.Fig. 4. Quantification of cortisol in dialysate from serum by LCxLC–MS/MS:
Representative chromatogram obtained from a pooled serum sample from intensive
care unit patients (FSC: 57 μg/L). Upper panel: d3-cortisol; lower panel: cortisol.
Seite 18Ion-suppression characteristics of the method were assessed by
connecting a T-piece between the chromatographic column and the ion
source. Using a syringe pump, a pure solution of cortisol and d3-cortisol
(each 500 μg/L) was delivered with a constant flow rate of 10 μL/min
into the T-piece. By this post-column infusion, a baseline offset was
generated in theMRM-traces of cortisol and d3-cortisol. The variation of
this baseline signal was observed upon injection of samples derived
from human sera.
Potential carry over was tested by injecting samples of the highest
quality control material in quadruplicate, immediately followed by
injection of a blank sample. The chromatogram of this sample was
inspected for peaks in the MRM traces of cortisol.
In order to determine stability of FSC we applied the “Guidance for
Industry” protocol suggested by the Food and Drug Administration
(FDA) [12]. We used two serum pools and investigated freeze and
thaw-, short-term temperature-, long-term-, stock-solution- and
post-preparative stability.
ED device comparison
As a final experiment, we investigated the agreement between FSC
results observed using ED devices from a different manufacturer
(Scienova Xpress Equilibrium Dialyzer, Scienova, Jena, Germany) by
comparative analysis of 16 samples. Apart from the ED devices, all ED
variables were identical in this experiment.
Results
We found excellent linearity with a coefficient of determination of
the 7 calibrator samples N0.999 in all validation series. Mean accuracy
of the three QC samples ranged from 94.6 to 102.5%. Interassay
coefficients of variation found for the three serum pools ranged from
3.1 to 9.8%. The raw data of the evaluation are given in Table 1.
LLOQwas 0.20 μg/L (mean accuracy: 105.6%, coefficient of variation:
10.4%; n=6). Linearity was observed far above the calibration rage,
with a mean deviation from the target result of −10.9% for a sample
with a cortisol concentration of 500 μg/L (n=6).
Comparison of calculated and observed results in spiking experi-
ments demonstratedameanspiking recovery of 108.9% (range: 105.4%–
113.1%) for the quantification of cortisol.
For the total serum cortisol reference material (ERM-DA 192), a
concentration of 96.10 μg/L was found, corresponding to −2.7% of
expected value (analysis without ED). A FSC concentration of 7.55 μg/L
(mean of three determinations) was found for this reference material.
In the two databases screened, we identified 4 relevant com-
pounds as potentially interfering with mass spectrometric detection
of cortisol and d3-cortisol according to similar molecular masses:
Three endogenous molecules (aldosterone, 18-OH-corticosterone and
tetrahydrocortisone) and one drug (prednisolone) were investigated
for interference by an experiment. We introduced pure solutions with
concentrations above the physiological range (c=200 μg/L) of
aldosterone (mass/charge ratio: 361.4), 18-OH-corticosterone
(363.2) and tetrahydrocortisone (365.5), as well as for prednisolone
(361.4), with a concentration of 1000 μg/L to our chromatographic
procedure. We did not observe peak signals in the MRM traces of
cortisol or d3-cortisol, respectively.
Analysis of dialysate obtained from pool samples using extended
chromatography did not disclose additional peaks with retention
times differing from that of cortisol. Only samples from intensive care
unit patients showed a minor peak, eluting earlier than d3-cortisol in
the MRM-trace of d3-cortisol (366N121). This peak was base-line
separated using the standard chromatographic conditions (Fig. 4).
No evidence of ion suppression or carry over effects was observed.
In the stability experiments (freeze and thaw-, short-term
temperature-, long-term-, stock solution- and post preparative
stability tests) deviation of b10% from expected results was observed.
Table 1
Quantification of free serum cortisol by equilibrium dialysis and isotope dilution, two-dimensional liquid chromatography and tandem mass spectrometry: results of the method
validation study. Analysis of the spiked quality control (QC) samples 1–3 did not include ED. Results obtained in 12 validation series.
Pool low Pool medium Pool high
Observed concentration (mean) 2.33 μg/L 3.99 μg/L 56.8 μg/L
Total coefficient of variation (n=21 in 12 series) 9.8% 7.6% 3.1%
Intra-assay coefficient of variation (n=10) 9.8% 8.9% 3.5%
QC sample 1 QC sample 2 QC sample 3
Target concentration 1.00 μg/L 15.0 μg/L 45.1 μg/L
Observed concentration, mean 1.03 μg/L 14.9 μg/L 42.7 μg/L
range 0.87–1.15 μg/L 13.8–16.0 μg/L 40.7–45.7 μg/L
Accuracy, mean 102.5% 98.8% 94.6%
range −13.1–+14.6% −8.2–+6.5% −9.9–+1.3%
Total coefficient of variation (n=36 in 12 series) 7.4% 4.0% 2.8%
Intra-assay coefficient of variation (range; n=3 in 12 series) 2.1–14.4% 1.4–6.0% 0.2–4.7%
898 F. Kirchhoff et al. / Clinical Biochemistry 44 (2011) 894–899Post preparative stability investigation showed deviation of less than
5% from target results.
We found good agreement of FSC results obtained for 16 samples
using different commercially available EDdevices (y=0.8243x+0.1808;
r2=0.97).
During the time period of method validation we analysed more
than 300 samples for FSC in the context of a clinical study [13]. We
found good practicability of the protocol under these conditions of
larger scale application.
In healthy volunteers (n=47, male marathon athletes, sampling
between8and10 a.m.) ameanFSCof 13.1 μg/Lwas found (SD:5.3 μg/L)
with this method. Previously reported normal ranges for FSC are
16.5 μg/L (SD: 5.6 μg/L) for sampling at 8 a.m. and 2.3 μg/L (SD 1.8 μg/L)
for sampling at 10 p.m. [6].
Discussion
We here describe a convenient isotope dilutionmass spectrometry
method for the quantification of free, bioactive cortisol in serum;
evaluation data characterise this method as reliable and applicable for
both clinical studies and in the context of the development of routine
ligand binding tests for this innovative analyte.
In previous clinical studies we so far employed self manufactured
dialysis cells for the quantification of free serum cortisol [14]; here we
used convenient dialysis devices which have become commercially
available meanwhile. This realises a substantially higher degree of
standardisation and offers far better practicability, also allowing a
substantial throughput of samples.
For free hormone reference methods, ED is preferred to UF [15]
since it can be assumed that a forced filtration process can induce dys-
equilibrium artefacts on the site of the filtration membrane [16]. This
may potentially introduce bias in previously described FSC methods
[8–10]. In our experience, the technique of UF for FSC quantification is
furthermore flawed by a very substantial between-sample variation in
the yield of filtrate at a given constant centrifugal filtration time, often
with N100% differences in the volume of filtrates obtained from
different samples. The filtration, as well as the dialysis process has to
be performed at exactly 37 °C, due to the fact that the binding affinity
of CBG to cortisol is very sensitive to temperature variations [17,18].
Precise temperature control inside a centrifuge and of the filtration
devices however is difficult to obtain with commercially available
centrifuges; this compromises the reliability of UF methods for FSC
quantification [19]. For these reasons we assume ED superior to UF for
FSC measurement.
The unbound fraction of serumcortisol represents roughly one tenth
of the total cortisol concentrations and thus very low analyte
concentrationshave tobeaddressed.Our results, however, demonstrate
that reproducible quantification of this analyte does not require “high-Seite 19end” mass spectrometry instruments but can be achieved also using
standard LC–MS/MS equipment. By using on-line solid phase extraction
(also termed LCxLC), matrix effects on the ionisation of the target
analyte could be minimised in our method. No matrix induced ion
suppression was observed in our experiments. Potential occurrence of
ion suppression in individual samples is compensated for by the
principle of isotope dilution applied in this method.
For the method described herein acceptable reproducibility with
inter-assay CVs b10% for authentic samplematerials in a physiologically
very low concentration range was observed, as well as good accuracy
with b5% deviation from target concentrations for matrix-free spiked
samples. The development of an actual reference method for FSC
quantification based on our protocol must aim to improve the
reproducibility, to CVs of ideally ≤2%. This seems feasible when
applying latest high-end MS/MS instruments with superior signal-to-
noise characteristics compared to the system used here.
A drawback in the evaluation of FSC measurement is given by the
fact that authentic but analyte-free serum matrix for investigation of
accuracy by spiking experiments is not available. Thus, our results on
accuracy are restricted to the mass spectrometric analysis but did not
address the process of equilibrium dialysis.
Membrane leakage is an important and omnipresent potential
pitfall of ED. Gross leakage becomes evident from a serum-like colour
of the dialysate. We have observed this in about 2% of the dialysis
devices. Minor leakage, in contrast, may remain undetected by visual
inspection. The results of our imprecision study – where one sample
was excluded, due to serum-like colour of the dialysate – , however,
suggest that the degree of a device-individual micro-leakage was
minor. Nevertheless, analyses in duplicate should be considered
depending of the scope of application.
In a sub-set of evaluation samples we used dialysis devices from a
different manufacturer for comparison. Close correlation of the results
but an approximate 20% systematic bias was observed. This might be
explained by adsorption of the analyte to surfaces of protein-free
compartments of the comparison devices. Whatsoever, standardisa-
tion of dialysis devices seems important and also lot-to-lot variations
of ED devices must be assessed critically in the context of specifying a
reference method in the future.
The method described in this manuscript should undergo – after
this mono-centric evaluation – an extended multi-centric validation
process. Selectivity experiments applying extended chromatography
should be performed for individual instruments, since interference
from isobaric compounds can potentially occur in an instrument
specific manner [20].
Our method is also applicable for clinical studies; in particular,
reference ranges for FSC in the context of endocrine function testing
(e.g. ACTH stimulation test and dexamethasone suppression test)
should be established on a high level of reliability using an isotope
899F. Kirchhoff et al. / Clinical Biochemistry 44 (2011) 894–899dilution assay now. If this is realised, the method can as well be
applied for diagnostic purposes since LC–MS/MS becomes more and
more used in endocrinological clinical laboratories. Overnight
incubation for equilibrium dialysis might be acceptable also in a
routine setting, since turnaround-time is not critical in the diagnostic
work-up of suspected adrenocortical pathologies in most cases.
Dialysis devices create extra costs of approximately 7 € per sample
which also might be acceptable in a clinical setting.
It seems very likely that the diagnostic use of free serum cortisol will
result in superior diagnostic power compared to total serum cortisol
measurement, because of the substantial inter- and intra-individual
variation serum cortisol binding and the well-founded assumption that
only unbound cortisol is biologically active [21]. Salivary cortisol
measurementmaybe analternative to FSCmeasurement [22], however,
drawbacks of this approach have to be considered: Dissociation
between blood and saliva free cortisol levels under challenge conditions
are observed and discussed with respect to the presence of CBG also in
saliva [23,24]. Moreover, it must be considered that cortisol undergoes
enzymatical conversion to cortisone by 11β-hydroxysteroid dehydro-
genases in salivary glands to a considerable proportion with potentially
substantial between-individual variation. Furthermore, reliable collec-
tion of saliva is difficult in severely ill patients with suspected critical
illness related corticosteroid insufficiency (CIRCI).
Since ligand binding assays are still the predominant technology in
the clinical endocrinology laboratory worldwide, the introduction of
routine FSC tests on respective automated platforms – as was realised
for free thyroid hormones many years ago – is highly desirable. The
availability of a convenient isotope-dilution mass spectrometry
method– as described in this report – for analytical reassurance
during routine assay development might encourage the diagnostic
industry in the decision to develop such tests. This might be along the
lines of 25-hydroxyvitamin Dmeasurement, where LC–MS/MS is now
established and accepted as the key technology during the develop-
ment of reliable routine ligand binding assays [25,26].
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 Abstract 
 Background: Extensive sets of data are required to investi-
gate the potential use of a therapeutic drug monitoring with 
individualization of dosage of the antimycotic compound 
caspofungin. The goal was to develop an improved liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) 
method for this aim. 
 Methods: Following protein precipitation, on-line solid 
phase extraction was performed for sample preparation. As 
the internal standard compound the veterinary drug tylosin 
was used. A standard validation protocol was applied. 
 Results: Good reproducibility and accuracy of the method 
were observed. On-line solid phase extraction resulted in a 
convenient work-fl ow and good robustness of the method. 
 Conclusions: This improved LC-MS/MS method was found 
reliable and convenient. It can be suggested for further work 
on the clinical pharmacology of caspofungin in the setting of 
clinical research laboratories. 
 Keywords:  caspofungin;  liquid chromatography-tandem 
mass spectrometry (LC-MS/MS);  on-line solid phase extrac-
tion (SPE); tylosin. 
 Invasive fungal infections represent a leading cause of mor-
bidity and mortality in immunocompromized patients today. 
During the last decade the therapeutic armamentarium has 
expanded substantially and now includes almost 10 com-
pounds to be considered for prophylaxis and treatment of 
invasive fungal infections  (1) . Therapeutic drug monitoring 
(TDM) is increasingly discussed for each of these drugs, 
however  – in contrast to immunosuppressants used in trans-
plantation medicine  – guidelines for TDM of anti-mycotic 
drugs have scarcely been defi ned or evaluated  (2) . 
 For the triazole compounds (itraconazol, posaconazol, vori-
conazol) chromatographic and mass spectrometric methods 
are now available in a substantial number of clinical research 
centers; the analytics of the more novel group of echinocan-
dines has been addressed only by a few groups so far. Among 
the echinocandines, on the one hand caspofungin plays the 
most important role in clinical practice to date, on the other 
hand a higher incidence of side-effects and potential for drug-
drug interactions is known for caspofungin  (3) . 
 Caspofungin steady-state concentrations in plasma between 
0.25 and 2.5  mg/L have been described for different admin-
istration regimens  (4) ; clinically relevant caspofungin levels 
range up to approximately 10  mg/L  (5) . 
 The aim of our work was to develop a reliable liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) 
method for respective clinical investigations, applicable in 
the setting of routine laboratories, thereby addressing some 
limitations of previously published methods (see online 
data Supplemental Appendix 1). Beyond published work on 
caspofungin measurement by LC-MS/MS two issues were 
addressed by our work in particular: investigation of a suited 
and commercially available compound for internal stan-
dardization and development of a semi-automated sample 
preparation protocol based on on-line solid phase extraction 
(SPE) prior to a standard LC-MS/MS system. This principle 
has been used in our laboratory for over 10  years now and is 
found to enable very robust methods with short run times and 
minimal down-times required for maintenance. 
 Twenty-fi ve microliters of calibrator, quality control sam-
ple, or serum was shortly vortexed with 50  μ L of phosphate 
buffered saline (PBS) solution in 1.5  mL polyproylene cups. 
Thereafter 75  μ L of internal standard (IS) working solution 
[approx. 100  μ g/L tylosin in acetonitrile/methanol (9:1 by 
volume)] was added. Cups were shaken for 10  min using a 
horizontal shaker. This was followed by centrifugation for 
10  min at 15,000  g . Ten microliters of each supernatant was 
injected into the LC-MS/MS system (Waters Alliance 2795 
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HPLC module; Waters, Milford, MA, USA), coupled split-
less to a Micromass Quattro Micro tandem mass spectrom-
etry system; mass spectrometric conditions are listed in the 
online data Supplemental Appendix 4. Sample clean-up was 
performed online using on-line SPE. 
 Supernatant was injected and loaded onto a Waters Oasis 
HLB column (2.1 × 20  mm; 25  μ m particle size; Waters, 
Milford, MA, USA) in valve position A (scheme of the on-
line SPE is given in Figure  1 ). The mobile phase was water/
methanol 90/10 (v/v), delivered at a fl ow rate of 4  mL/min. 
Potential interfering compounds were washed into waste. 
In parallel, the analytical column (xTerra C-8, 2.1 × 50  mm; 
3.5  μ m particle size; Waters, Milford, MA, USA) was equili-
brated with 70/30 (v/v) acetonitrile/15  mM ammonium for-
mate, delivered at a fl ow rate of 0.2  mL/min. After 1  min, 
the switching valve was changed to position B; the extraction 
column was now eluted in a back-fl ush mode onto the analyti-
cal column. After another 2  min, the valve was switched back 
to position A. During the analytical chromatography into the 
mass spectrometer in position A, the extraction column was 
washed for 1  min with 80/20 (v/v) methanol/1 % formic acid 
at a fl ow rate of 4  mL/min. The total run time was 3.5  min. 
 For quantifi cation, we applied 1/x fi t weighting of the peak 
area ratios of analyte/IS vs. the concentration to obtain the 
calibration curves. 
 Calibrators were made by diluting the working solution 
of caspofungin (see online data Supplemental Appendix 5) 
with drug-free human serum to obtain caspofungin concentra-
tions of 20.0, 10.0, 5.0, 2.5, 1.25, 0.62 and 0.31  mg/L. In the 
same manner, we prepared quality control samples in three 
concentration levels (16.0, 1.6 and 0.4  mg/L). We used one 
serum pool, in order to additionally study the imprecision 
of the method. This pool was prepared from residual serum 
sent for standard clinical chemistry analyses from patients, 
treated with caspofungin. Aliquots of quality control samples, 
calibrators and serum pool were stored in polypropylene vials 
at  – 80 ° C. 
 In 11 analytical series, applying full calibration, we dem-
onstrated mean accuracy ranged from 94.0 % to 97.3 % and 
coeffi cients of variation (CV) below 8 % (complete data is 
shown in online data Supplemental Appendix 2). The coef-
fi cient of determination of the seven calibrator samples was 
 > 0.99 (R 2 ) in all series (average y-intercept and slope values: 
y =1.01x − 0.03157). 
 Lower- and upper limit of quantifi cation (LLOQ, ULOQ) 
were assessed by analyzing different concentrations of 
spiked drug-free serum in duplicate in three runs. LLOQ was 
0.25  mg/L and ULOQ was 40  mg/L for caspofungin (crite-
rion for acceptance: accuracy of 80 % – 120 % , precision with 
a CV < 20 % ). 
 Specifi city of the method was demonstrated, when analyz-
ing 50 samples from residual serum of intensive care patients. 
None of the samples showed peaks in the multiple reaction 
monitoring (MRM) trace of caspofungin. 
 Ion-suppression characteristics of the method were assessed 
by connecting a T-piece between the chromatographic col-
umn and the ion source. Using a syringe pump, a pure solu-
tion of caspofungin (approx. 1  mg/L) and tylosin (0.1  mg/L) 
was delivered with a constant fl ow rate of 10  μ L/min into 
the T-piece. By this post-column infusion, a baseline offset 
was generated in the MRM-traces of caspofungin and tylo-
sin. At the respective retention times we did not observe any 
signifi cant variation of this offset upon injection of human 
serum samples, ruling out relevant ion suppression by resid-
ual matrix components. 
 To verify recovery of the method, aliquots of a serum pool, 
from patients treated with caspofungin, was spiked with dif-
ferent amounts of caspofungin working solution, resulting 
in fi ve different concentration ranges. Quantifi cation in the 
absence and presence of addition of caspofungin working 
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 Figure 1  (A) Scheme of the on-line solid phase extraction system (AC, analytical column; W, waste; MS, mass spectrometry system). (B) 
Representative MRM chromatograms obtained from a pooled serum sample (caspofungin approx. 2.5  mg/L). Upper panel: tylosin. Lower 
panel: caspofungin (retention time approx. 2.35  min); total run time: 3.5  min. Arrows indicate switching valve positions. 
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solution resulted in a mean recovery rate of 92.5 % (range: 
83.3 % – 99.3 % ). 
 Recovery of the two-step extraction process was evaluated. 
Samples in three concentration levels were analyzed with and 
without the on-line SPE procedure. A pure solution of caspo-
fungin in 20 % human serum albumin was directly injected 
onto the analytical column, by omitting the on-line SPE pro-
cedure, whereas spiked serum samples in the same concentra-
tion levels were submitted to the entire analytical process. A 
mean signal recovery of 111.7 % was found (n = 9). 
 Carry-over was evaluated by injecting the highest QC 
sample 10 times, immediately followed by a blank sample. 
The chromatogram of this sample was inspected for peaks in 
the MRM trace of caspofungin and resulted in a carry-over 
effect of  < 1 % . 
 Stability of precipitation extracts was evaluated by reanal-
ysis of deproteinized samples of a calibration series, 24  h after 
their initial analysis. Extracts obtained by protein precipita-
tion were found stable for at least 24  h  – a mean deviation of 
105.5 % of the peak areas of the MRM trace of caspofungin 
was noted (n = 6). 
 In this article a convenient LC-MS/MS method for quanti-
fi cation of caspofungin in serum is described; validation data 
characterize the method as applicable for clinical research 
use. Regarding previously described LC-MS/MS methods 
for the quantifi cation of caspofungin in blood, our method is 
novel with respect to the IS compound and with respect to 
a convenient semi-automated sample preparation protocol: 
in three of the previous methods  (6 – 8) an isoster of caspo-
fungin is used as the IS. This compound may be suited, but 
was obtained from the manufacturer of caspofungin and is 
not commercially available; thus the method cannot easily be 
reproduced. Decosterd et al.  (9) rely on stable isotope labeled 
voriconazole for internal standardization. This is questionable 
as well, since molecular weight and molecular structure of this 
compound is completely different from that of caspofungin. 
The compound tylosin, however, has a heterocyclic structure, 
as is the case for caspofungin, and a similar molecular weight 
(see online data Supplemental Appendix 3). It is commercially 
available and not in use in human medicine, but exclusively 
in veterinary medicine. Therefore, we considered tylosin to 
be a good candidate for use as IS; this was confi rmed by our 
validation results. Egle et al.  (10) completely abdicate the 
use of an IS, which is very uncommon in clinical mass spec-
trometry. Also, a complex and fully automated LC-ion trap 
MS method for caspofungin quantifi cation in serum, which 
requires two switching valves, two gradient HPLC pumps, a 
complicated chromatographic set-up and very extended chro-
matographic run times is described. In our experience, such 
application of crude serum to on-line extraction cartridges 
may be convenient but is hampered by the very limited life 
time of the extraction materials. Applying protein precipita-
tion prior to simple on-line SPE, an extended performance of 
the extraction columns and –  compared to direct analysis of 
deproteinized samples to HPLC  –  very good ionization effi -
cacy is guaranteed. 
 In agreement with previous articles, we identifi ed three 
particular problems for quantifi cation of caspofungin using 
LC-MS/MS: linearity of response over a wider calibration range 
 (6 – 8, 10) ; adsorption of the analyte to surfaces  (7, 11 – 13) ; and 
asymetrical peak shape due to isomers of the analyte  (8, 10) . 
Regarding linearity issues we found dilution with PBS nec-
essary to obtain acceptable calibration functions. Adsorption 
problems as carry-over issues should be addressed by rather 
long washing cycles and high proportions of organic solvents. 
Sub-optimum peak shape due to isomers (as demonstrated in 
Figure 1) requires consistent peak integration criteria. 
 In summary we suggest the use of tylosin as an IS together 
with on-line SPE after protein precipitation as an alternative 
for quantifi cation of caspofungin in blood using LC-MS/MS. 
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Background: LC-MS/MS is an almost universal technology for the quantification of small molecules in
human sample materials. The widespread use of this technology in laboratory medicine is so far limited
mainly by the extensive occupation of highly trained personnel which is required for method
implementation and application. Furthermore, robustness of function and results is still a critical issue of
routine quantitative applications of LC-MS/MS.
Content: This article reviews approaches to the automation of essential processes of LC-MS/MS applications
in clinical laboratories. Furthermore, perspectives of further steps towards highly robust and fully automated LC-
MS/MS methods and instrument configurations are discussed.
Conclusions: There is a variety of efficient approaches to automation of LC-MS/MS methods in use which
mainly address sample preparation. Such configurations allow a substantial increase of sample throughput and
conveniencewhen compared to standardprotocols.However, these applications still have tobe implemented for
individual methods in heterogeneous instrument configurations and still require highly trained experts. Based
onexisting technologies, however, thedevelopment of fully automated LC-MS/MS front-endmodules orMS/MS-
based analyzers which offer a degree of user-friendliness and robustness similar to current standard clinical
chemistry analyzers seems feasible today. Only such systems will make the entire analytical potential of LC-MS/
MS amenable to clinical medicine also outside from tertiary care centres.
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Standard techniques of analyte detection in clinical chemistry rely
on indirect characteristics of an analyte, e.g. its absorption of light,
chemical reactivity or physical interaction with macro-molecules. In
mass spectrometric methods, in contrast, analytes are detected
directly from molecular characteristics as molecular mass and
molecular disintegration patterns. Thus, mass spectrometric techni-
ques are very attractive for the quantification of biomarkers or
xenobiotics in the context of diagnostic procedures, since those
techniques can enable analyses of much higher specificity compared
to standard technologies such as photometry or ligand binding tests.
With gas chromatography–mass spectrometry (GC–MS), first mass
spectrometric methods were introduced to laboratorymedicine about
40 years ago. GC–MS allowed the highly specific and sensitive
quantification of thermo-stable molecules below a molecular weight
of about 500. Thus, GC–MS became a key technology, e.g. in
toxicology. With respect to standardisation and quality assurance of
small molecule analytical routine methods the introduction of GC–MS
as a reference method was an essential progress, in particular for
endocrinology. However, for several reasons the application of GC–MS
remained restricted to few specialized institutions in laboratory
medicine (mainly toxicological laboratories, metabolism centres, and
reference laboratories). The handling and maintenance of GC–MS
instruments is very demanding and time-consuming; sample prep-
aration is very laborious and includes sample extraction and analyte
derivatisation; the analytical run times are long with a typical sample
throughput of less than 50 samples per day.
The introduction of atmospheric pressure ionisation techniques
about 20 years ago made practically all potential bio-medical analytes
amenable for mass spectrometry. Furthermore, powerful new
technologies of ion-analyses (tandem mass spectrometry, time-of-
flight mass spectrometry, ion-trap mass spectrometry) substantially
increased the capabilities of MS analyzers with respect to specificity
and to the extent of data read-out in the 1990s. These developments
suggested a widespread use of mass spectrometric methods in routine
laboratory medicine.
In particular tandem mass spectrometry (MS/MS) instruments
hyphenated to liquid chromatography (LC) systems used for sample
introduction and pre-fractionation have been implemented in a
constantly growing number of clinical laboratories worldwide now
[1]. These instruments are mainly used for small molecule analyses in
neonatal screening of inborn diseases of metabolism and therapeutic
drug monitoring but also in endocrinology and toxicology, while
applications for peptide and protein quantification are not yet used in
routine laboratories.
LC-MS/MS is attractive for laboratory medicine for three main
reasons.
- the development of new methods is in general straightforward
and independent from the diagnostic industry, without the need
e.g. to develop analytical antibodies
- highly multiplexed analyses are feasible with very low current
costs; the range of potential analytes is practically unlimited;
individual “metabolomic analyses” addressing hundreds of ana-
lytes from different biochemical pathways and from different
chemical classes are possible, as well as a comprehensive and
individual description of xenobiotics (“xenobiom”).
- when applying the principle of isotope dilution internal standar-
disation, analyses on a reference method-level of accuracy can be
performed in a routine laboratory setting.Seite 28Characteristics of current standard LC-MS/MS applications
When compared to contemporary clinical chemistry or immunoa-
nalyzer systems, however, the practicability and also the robustness of
standard LC-MS/MS configurations is still poor. A multi-step prepa-
ration of diagnostic samples – mainly aiming to remove macro-
molecules – is required; preparation of samples typically includes
manual labelling of several secondary tubes; manual data input to
sample list is necessary; individual inspection of chromatograms is
necessary as well as the manual transfer of results to a laboratory
information management system (LIMS); instrument handling
includes open manipulation of toxic compounds and several sub-
systems of the instrument configuration have to be monitored
(solvent and oil levels, gas flows, temperatures). Maintenance
procedures and trouble shooting in LC-MS/MS instruments are
typically poorly standardized and can be a substantial challenge for
the user. LC-MS/MS methods have to be developed and/or imple-
mented by the end-user to very heterogeneous instrument config-
urations. This also includes minute supervision of the assay
performance. Typically far longer down-times must be expected in
case of technical problems compared to contemporary clinical
chemistry analyzer applications. Consequently, for method imple-
mentation and support, highly trained personnel are required in a
clinical laboratory if an acceptable degree of robustness has to be
maintained.
LC-MS/MS today holds enormous potentials for improvements in
laboratory medicine (mainly in therapeutic drug monitoring, endo-
crinology, toxicology, and metabolomic analyses) but the features of
standard instruments are at present hardly compatible with thework-
flow of contemporary standard clinical laboratories. Development of
solutions for extensive automation is clearly the key to a widespread
application of LC-MS/MS in laboratory medicine in the future.
Most of the developments in LC-MS/MS automation originated
from applications in the pharmaceutical industry [2–6]. In this field,
LC-MS/MS has become a key technology for pharmacokinetic studies
and on all levels of drug development. Typically large series of
samples have to be analyzed for single drug candidates on a good
laboratory practice (GLP) level. Consequently, automation in pharma-
ceutical industry targets extended batch analyses. In pharmaceutical
research laboratories but also in environmental and food testing
laboratories typically highly trained technicians are available and the
number of different analytical technologies is small. In clinical
laboratories, in contrast, the availability of skilled technicians is
increasingly a critically limited resource in many countries. Conse-
quently, the need for automation is far more pronounced in medical
diagnostics application of LC-MS/MS when compared to “traditional”
main areas of application of this technology.
In different clinical laboratory MS units' work-flows and the range
of applications are quite heterogeneous. In commercial referral
laboratories, large series for few analytes may be typical (e.g., 25-
hydroxyvitamin D, plasma metanephrins, androgens, immunosup-
pressants, methylmalonic acid). Often one instrument system is
permanently used for one method. Since turnaround time is less
critical in these cases, analyses can be run in a batch mode which can
favourably be automated with generic liquid handling systems in a
micro titer plate (MTP) format, similar to applications in drug
development. In hospital laboratories, in contrast, a far wider range
of parameters is typically intended to be quantified using a limited
number of LC-MS/MS instruments andwithin a short turnaround time
(in particular with respect to therapeutic drug monitoring). It is
generally desired to develop generic methods for a class of analytes
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between methods (including solvents and columns) is typically
necessary in such a setting. In particular, such change of methods
impairs the work-flow and is prone to down-times. Thus, it is evident
that the requirements for automation differ substantially between
hospital laboratories and commercial medical laboratories. While the
concept of a paralleled batch-processing is appropriate for referral
laboratories, for hospital laboratories automation aiming to a random-
access, multi-channel work-flow is clearly preferable.
Scope of automation
Automation has to address a number of different processes in
laboratory medicine application of LC-MS/MS; this includes manage-
ment of primary samples, assay-specific work-up of samples prior to
actual MS analysis, integrated control of the subunits of LC-MS/MS
systems, processing of primary read-outs, and further handling of
result data.
During recent years it has become evident thatmost and even all of
these issues can be subject to automation.
Besides (and beyond) reducing manual work-load, automation in
LC-MS/MS also aims to increase the reliability of results by avoiding
gross errors.
Solutions for automation in LC-MS/MS are so far predominantly
home-made and based on generic components (e.g., liquid handling
robotic systems, switching valves, autosamplers) while dedicated
systems for this aim are hardly commercially available at present.
Solutions of automation are applied in a growing numbers of
laboratories andwere successful in increasing the throughput.However,
automation has still not yet overcome the fact that LC-MS/MS is
applicable only in rather few, highly specialized clinical laboratories to
date.
Partial Automation of HPLC analyses has long been established by
introduction of autosamplers which inject defined volumes of sample
extracts and by introduction of programmable gradient pumping
systems which modify the composition of the mobile phase during an
analytical run. These components are still important for reliable
results. In particular potential carry-over of autosamplers has to be
addressed. Beyond autosamplers, without doubt most efforts of
automation in clinical LC-MS/MS have so far addressed sample
preparation for batch analyses [7].
In the following sections we will describe the now widely used
tools of automation in sample preparation, as well as emerging
techniques. Further on we will discuss the perspective of fully
automated LC-MS/MS systems which might become compatible
with the work-flow and characteristics of today's standard clinical
laboratories in the future.
Automation of sample preparation
Requirements of sample preparation in LC-MS/MS
So far, application of LC-MS/MS in clinical chemistry involves to
the quantification of small molecules in blood and urine while
analysis of peptides and proteins is a future perspective. Thus, in
present methods a key requirement of sample preparation is to
remove peptides and proteins from the sample. Peptides and proteins
are incompatible with standard chromatographic set-ups since HPLC
columns would be blocked after few injections [5]. Furthermore,
peptides tend to interfere with atmospheric pressure ionisation by
occupying protons and generate substantial background “noise”.
Beyond de-proteinization, sample preparation for LC-MS/MS aims
to deplete further compounds which impair the ionisation of target
analytes (e.g., salts, polar compounds as amino acids) and to deplete
compounds which cause unspecific signals (such as phospholipids).
For many analytes of low abundance, sample preparation aims toSeite 29concentrate the analyte in order to decrease lower limits of
quantification; while for other analytes dilution is necessary (in
particular when using high-end analyzers) in order to avoid
saturation effects of detection and non-linearity. Removal of salts
also minimizes contamination of the ion source and is thus relevant
for robustness.
During a decade of LC-MS/MS application in the clinical laboratory
the preferences for the purity of samples injected to the LC-MS/MS
system has changed to some degree. In the earlier years a
straightforward “dilute-and-shoot” approach was widely approved.
Now an efficient and selective sample preparation is more and more
advocated which substantially limits ion-suppression effects. On the
other hand, with increasing sensitivity of MS/MS detectors, concen-
tration of target compounds during sample preparation becomes
necessary for a decreasing number of analytes. Efficient removal of
proteins (beyond the efficiency of simple protein precipitation) also
becomes increasingly important with respect to the lifetime of
innovative sub-3 μm columns. These columns enable highly efficient
chromatographic fractionation, but are easily blocked by residual
proteins.
A less stringent sample preparation may be tolerable with respect
to ion suppression if extended chromatography is applied; on the
other hand, very selective sample preparation can potentially reduce
the demands of chromatographic fractionation in some LC-MS/MS
applications. Thus, sample preparation and chromatographic frac-
tionation of a method interact and should be looked upon as one
functional system.
The evident final goal for the automation of sample handling and
preparation in LC-MS/MS is evidently to allow the introduction of
crude serum or plasma, whole blood (where necessary) or urine into a
hyphenated sample preparation/LC-MS/MS systems with no need for
any further manual intervention. Centrifugation and de-capping of
primary blood sampling containers is done by use of a central pre-
analytic automate in many laboratories now; thus, introduction also
of these very essential steps of laboratory sample management into a
LC-MS/MS pre-analytic module does not seem useful.
Basic principles of sample preparation
Four main principles of sample extraction are applied in liquid
chromatography: Protein precipitation (PPT) (by addition of organic
solvents, inorganic acids and/or chaotropic salts); protein filtration;
solvent extraction (syn. liquid–liquid extraction, LLE); and solid phase
extraction (SPE).
Protein precipitation is straightforward, but does not allow
concentration of the analytes; instead, typically a dilution of at least
1:2 is obtained. Typically not a very high degree of protein removal is
achieved. Solvent extraction and solid phase extraction – based on
differential solubility and surface affinity of target analyte and
potentially interfering compounds – typically result in very clean
extracts; ion-suppression effects due to residual matrix components
are reduced with solvent extraction and solid phase extraction
compared to mere protein precipitation [8,9]. While LLE is predom-
inantly based on differential polarity, a variety of different extraction
surfaces is available for SPE (such as carbohydrates (C2, C8 and C18),
ion exchange materials [10,11], phenylic groups, amino groups, co-
polymer mixed mode materials [12], immobilized on particles packed
in cartridges). Therefore, SPE can address much more specifically
molecular characteristics of target analytes and allows the design of
protocols which are far more analyte specific compared to LLE.
Consequently, the principle of SPE is the most versatile method to be
used for sample preparation. SPE materials can have added particular
functions, as removing of phospholipids. Both LLE and SPE allow up to
ten-fold concentration of analytes; however, these methods are
technically far more demanding compared to PPT. The optimum
choice of one of the four main principles of sample preparation is
Fig. 1. Automated liquid handling system employed for sample preparation for LC-
MS/MS. Worktable of the Tecan Freedom EVO pipetting system. 1, sample trays with
decapped whole-blood samples; 2, barcode reader; 3, liquid handling arm with four
pipette carriers; 4, disposable pipetting tips; 5, 96-position 2-mL deep-well plate on a
horizontal shaker; 6, dropping station for used pipette tips; 7, chilled reagent troughs
(internal standard and precipitation solution, respectively); and 8, washing station.
from [13].
7M. Vogeser, F. Kirchhoff / Clinical Biochemistry 44 (2011) 4–13specific for the respective analyte but also for the individual MS/MS
system.
While automated solvent extraction is rarely used in clinical LC-
MS/MS applications, automated solid phase extraction (SPE) is widely
used now. SPE materials can be packed in single use cartridges, in
single use 96 position arrays or they can be packed within
permanently used extraction cartridges used for on-line SPE. In
many applications precedent protein precipitation is combined with
SPE, in particular with on-line SPE.
“Paralleling” automated sample preparation protocols in 96
position arrays – based on protein precipitation, protein filtration,
or SPE – result in batching of analyses, which is useful for some
settings, as mentioned above. However, in many hospital laboratory
applications of LC-MS/MS, a sequential, sample-by-sample approach
of automation is preferred. For such an aim – e.g. in therapeutic drug
monitoring with desired short turnaround times – on-line SPE after
preceding protein precipitation using single vials is often applied now.
Automated liquid handling systems
Paralleled sample preparation solutions for LC-MS/MS based on
96-position arrays can be operated manually (as is the case for ELISA
tests in most laboratories) but are typically run on generic liquid
handling robotic systems. Such instruments are configured to prepare
extracts into a secondary sample carrier which is then manually
transferred into the autosampler of the LC-system, representing an
“off-line” solution. This approach is discontinuous but has the
strength that one sample preparation module can potentially be
used for several LC-MS/MS systems. Respective robotic platforms are
available from a number of companies (e.g., Tecan (http://www.tecan.
com), Hamilton (http://www.hamiltoncompany.com), Gilson (http://
www.gilson.com), PerkinElmer (http://www.perkinelmer.com),
Zinsser (http://www.zinsser-analytic.com), Beckman Coulter
(http://www.beckmancoulter.com)). They represent “open” systems,
allowing flexible configuration of many different devices (e.g., bar
code readers, vacuum stations, pipette arms, grippers for micro titer
plates, shaker). Such platforms are widely used for ELISA handling or
in the context of blood banking. Also for the processing of LC-MS/MS
batch analyses comprehensive liquid handling systems have been
used for more than a decade now, particularly in the field of drug
development. Advanced autosampler systems with robotic compo-
nents are also increasingly used for sample preparation procedures
(e.g., from CTC PAL (http://www.ctc.ch) or Gerstel (http://www.
gerstel.com)).
Robotic liquid handling systems for sample preparation typically
also perform addition of the internal standard solution into a sample
aliquot, but potentially also bar code reading of primary tubes and
generation of a sample list [13] (Fig. 1).
Direct coupling of a sample preparation module with the LC-MS/
MS system potentially also allows automated sample injection and a
“walk-away” mode of working [14,15].
In the following sections the different strategies of automated
sample preparation are discussed.
Automated protein precipitation (PPT)
For manual handling, protein precipitation is the most convenient
technique of sample preparation. After addition of the internal
standard solution and addition of a precipitation liquid (e.g.,
methanol, acetonitrile, zinc sulphate and perchloric acid) the sample
is centrifuged for several minutes in a bench-top centrifuge (at
N10000 g) and a water-clear extract is obtained. Full automation of
protein precipitation, however, is difficult, since a centrifuge has to be
incorporated into a sample preparation module [16]. However,
automated transfer of sample aliquots from primary tubes into a
MTP, automated addition of internal standard and precipitationSeite 30cocktails for subsequent off-line centrifugation and transfer of the
MTP to an autosampler is an attractive option for batch analyses
[13,16,17,18]. Notably, only few types of centrifuges allow centrifu-
gation of MTPs on g-levels which are required for efficient
deproteination of plasma samples.
Automated protein filtration
Protein filtration – with or without prior addition of protein
precipitating fluids – can be automated when applying vacuum or
positive pressure to filtration cartridges. Proteins are retained by
single use filtration membranes, and protein free filtrate is collected.
Such protocols are typically applied in a 96-array plate format [19]. In
contrast to protein precipitation, automated removal of proteins can
be achieved without manual intervention (as is required for the
transfer of plates into a centrifuge when applying protein precipita-
tion). However, the expenses for single use protein precipitation
plates are relevant.
Automated solvent extraction
Also solvent extraction can be subject to automation, albeit with
substantial effort [20]. Respective methods are mainly used in food
and environmental analyses where large and inhomogeneous sample
volumes (e.g., soil samples) have to be processed. Recent modifica-
tions of solvent extraction use gel-like materials (immobilized liquid
extraction) with a perspective of more straightforward automation.
Automated solid phase extraction
The most widely used principle for automated sample preparation
in LC-MS/MS is so far solid phase extraction (SPE). Such methods can
be based on single use extraction cartridges (Gilson, Aspec); on
extraction plates in a microtiter plate format; on permanently used
extraction cartridges within the HPLC system (also referred to as on-
line solid phase extraction, or two-dimensional LC); and on
ferromagnetic micro-particles. If crude serum or plasma without
previous protein precipitated is applied to SPE materials, a re-use of
extraction devices is usually not possible. If deproteinized samples are
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for up to thousands of analytical cycles.
SPE protocols include the following steps: activation and condition-
ing of the extraction material, e.g. by an organic solvent followed by
water; application of the sample with adsorption of the target analytes;
washing of the loaded extractionmaterial; elution of the extract; in case
of re-use, washing and re-equilibration of the extraction material. A
wide range of SPE materials is available today and a highly efficient
extraction protocol can be tailored for practically all analytes by
optimizing the content of organic solvents, pH or ion strength.
On-line solid phase extraction
On-line solid phase extraction after precedent protein precipitation
is the most simple and probably the most widely used approach of
automation in clinical LC-MS/MSapplication at present. Inmost cases an
additional isocratic HPLC pump and a six-port high-pressure switching
valve is used together with an extraction column [21,22], but more
sophisticatedconfigurationsare used aswell [23].Deproteinized sample
is injected by the autosampler onto the extraction column in a flow of
mobile phase containing a low proportion of organic solvent. Here the
analytes are retained; residual polar matrix components (amino acids
and salts) are not retained and are washed into the waste. Using the
switching valve, the flow of the additional pump containing a high
proportion of organic solvent is directed onto the extraction column in a
back-flush. Thus, the analytes are eluted from the extraction columnand
are transferred to the analytical column of the chromatographic set-up
(Fig. 2). Such a configuration requires connection of tubing according to
a relatively complex scheme, and the control of the switching valve by
the chromatography software. In addition, one additional reservoir of
mobile phase has to behandled. However, once implemented, the use of
on-line SPE is convenient.
An on-line SPE cycle typically takes about 30 to 60 s of additional
analysis time per sample. Short standard C-18 columns can be used as
the trap column, but in most cases dedicated on-line SPE columns are
used.Modernpolymericmaterials, and also co-polymermaterialswith
a polar and an apolar constituent allow a wide range of applications
[24–28]; also ion exchange materials are available [10,11,29].
A variant of on-line SPE applies the principle of turbulent flow
chromatography (TFC); very high flow rates generate specific
distribution effects dependent on the molecular size of components
on restricted access materials which can result in favourable clean-up
properties [30–34]. Applications for the direct injection of serum or
plasma have been described for TFC [35] but also for other SPE
materials [36]; however, the lifetime of the extraction columns is inFig. 2. Typical on-line solid phase extraction configuration. Plumbing of the six-port swi
chromatography step. (A) In the load sample position of the valve (right, 1 → 2), the speci
(yellow arrow) is flushed onto the first chromatographical stationary phase (SPE column). (B
onto the SPEmaterial is elutedwith the HPLC solvent (yellow arrow) and transported throug
from [66].
Seite 31general extended substantially by use of deproteinized samples
instead of crude serum.
Very high back-pressures in UPLC were first considered to be a
problem for on-line SPE configurations, however, respective solutions
have been described now [37].
The improvement in robustness and sensitivity – by reducing ion-
suppression – achieved by on-line SPE for sample clean-up may be
substantial for some analytes and some analyzers, or may as well be
marginal for others. There are few published data on direct
comparison of methods applying mere protein precipitation com-
pared to methods applying on-line SPE [38].
The additional analysis time of typically 1 min required for on-line
SPE can be considered substantial with short overall analysis times of
about 3 min in many assays now. Furthermore, additional highly pure
and expensive liquids have to be used. An additional pump and the
switching valve introduce further potential sources of technical
failures when compared to methods with simple (one-dimensional)
chromatography of deproteinized samples. Many modern API ion
sources can be removed and cleaned very easily causing minimal
down-time; therefore, more pronounced source contamination found
when not applying additional clean-up after protein precipitation can
be accepted by many users.
Nevertheless, on-line SPE is a standardmethod inmany laboratories
today. Recently commercial LC-MS/MS assay kits for the quantification
of 25-hydroxyvitamin D and of immunosuppressant involving on-line
SPE have been introduced (Chromsystems, Munich, Germany).
Automated off-line solid phase extraction
On-line SPE requires only little additional instrumentation but
allows only partial automation by substituting manual extraction
procedures. Automated off-line SPE, in contrast, can realize a far
higher degree of automation but requires a robotic liquid handling
system [3,4,39,40].
A typical work-flow protocol includes bar code reading of serum or
plasma sample tubes; (potentially re-suspension of whole blood
samples); transfer of a sample aliquot into a MTP well; addition of the
internal standard solution to the well; mixing; conditioning of the
extraction material (single cartridge or cell in a 96-position array);
application of sample spiked with the internal standard to the SPE
material; paralleled washing; paralleled elution of the extract from
the extraction material into a second MTP, which can be sealed for
subsequent LC-MS/MS analysis. In most systems 4 to 8 pipetting
channels are operated. Vacuum or positive pressure has to be applied
to achieve a sufficiently speedy transfer of fluids through the SPEtching valve located in the column compartment and connecting the SPE and HPLC
men aliquot delivered from the autosampler with the solvent flow from the SPE pump
) In the elute sample position of the valve (left, 1→ 6), the specimen fraction adsorbed
h the second chromatographical stationary phase (HPLC column) to theMS/MS detector.
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single use disposable tip solutions are available. The costs per sample
for single use extraction materials are in the range of 2–4 Euro.
“Off-line” SPE can be convenient for batch analyses of large series
which do not require short turnaround time for individual samples.
Without doubt, implementation and programming of a sample
preparation module requires experts, while the daily handling can
be reduced to few simple interventions as re-filling of liquids and
consumables, removing waste, and handling of the plates.
The off-line SPE approach using liquid handling instruments still
represents incomplete automation as long as MTPs containing the
sample extracts have to be transferred from the liquid handling system
to the HPLC autosampler by an operator. A direct coupling of a pre-
analytics module directly with a LC-MS/MS instrument is feasible as
well, either by a dedicated systems, as realized by the Spark Symbiosis
system (Spark Holland, The Netherlands) [14,15]; or by implementing a
HPLC injection valve onto a generic liquid handling system [41].
The Spark Symbiosis system should be mentioned here as the
most sophisticated instrument for complete automation of sample
preparation for LC-MS/MS today. It employs very small cartridges
available containing a variety of defined extraction materials.
However, the system primarily aims to the analysis of research
samples in micro-vials and is not yet useful for the direct application
of standard sample containers as used in clinical laboratories.
A wide range of different sample preparation protocols at present is
in use in clinical LC-MS/MS laboratories, from mere manual, non-
automated protein precipitation using centrifugation of single samples
and direct transfer of single vials to the LC-MS/MS system or direct
analysis of urine [42], over semi-automated on-line SPE protocols, to
almost completely automated SPE for large batches in 96-well arrays.
From the viewpoint of practicability, the first and very simple non-
automation protocol avoids additional instruments with their inherent
sources of malfunctions and enables de-batching which may be
important in the work-flow of many clinical laboratories [43]. The use
of a liquid handling system in contrast usefully requires batching,
resulting in extended turnaround times for an individual sample.
However, for applications where the turnaround-time (within a range
of 24 h) is less relevant – as for steroid or vitamin analyses – batching is
clearly preferable and a liquid handling system can certainly limit the
occupation of personnel to a substantial degree and help to avoid gross
errors in sample preparation as for example mixing-up of samples.
For most of the typical LC-MS/MS applications in laboratory
medicine fully or partially automated protocol have been described
and are in use (Table 1). Besides peer reviewed journals, application
notes of LC-MS/MSmanufacturers can be a useful source of information
about automated LC-MS/MS methods for individual analytes.
Emerging techniques of sample preparation
While SPE in a 96 position array, protein precipitation in an array,
and on-line solid phase extraction is used in many clinical MSTable 1
Examples of automation protocols for analytes which are quantified using LC-MS/MS in
many laboratories.
Analyte References
17-hydroxyprogesterone [67]
25-hydroxyvitamin D [25,34,68,69]
Androgens [32,70]
Antimycotic drugs [26,27]
Antiretroviral drugs [15,71]
CNS active drugs [31,72,73]
Drugs of abuse [74,75]
Immunosuppressants [24,33,66,76–78]
Metanephrins [10]
Methylmalonic acid [79]
Seite 32laboratories now, several further methods of sample preparation may
become useful for clinical LC-MS/MS applications in the future. Some
of them are already in use, e.g. in environmental and food analyses.
Solid phase extraction materials can be packed into pipetting tips;
the steps of solid phase extraction can be performed within these tips
by automated pipetting of sample, washing solution and finally
elution medium with direct injection of the eluate into an injection
port (ZipTip principle; Millipore (http://www.millipore.com) [44]).
A clear separation between sample preparation and chromato-
graphic fractionation can indeed be overcome. For the Nanomate
System from Advion (http://www.advion.com) [45] an application for
immunosuppressant quantification is described with automated
clean-up of the haemolysed samples by chromatographic zip-tips
and direct injection to an 400 nozzle nano flow-ESI chip source
without further chromatographic separation (application note).
Solid phase extraction materials can be packed in permanently
used syringes of autosamplers as well. This principle is also referred to
as solid phase micro extraction (SPME) or microextraction by packed
sorbents (MEPS) [46–50]. Respective methods can be implemented in
modern high-end autosampler devices (e.g., CTC PAL) and may
represent an alternative to on-line SPE.
Ferromagnetic micro-particles with modified surfaces (e.g., C-18
material) might be interesting for the automation of sample
preparation for chromatographic methods as well [51]. Such particles
represent a solid phase, however, can be handled in a suspension as a
liquid. The use of such particles in mass spectrometry might parallel
the achievements in the automation of heterogonous immunoassays
which also require a convenient handling of solid phases. Ferromag-
netic particles may also be handled within a HPLC system [52].
Approaches of sample preparation for mass spectrometry also
include miniaturized “lab-on-the-chip” solutions, as realized by
Agilent (http://www.agilent.com) for microfluidic applications [53].
Robustness and reliability
In general, today's MS/MS detectors – representing the core unit of
the entire LC-MS/MS analytical configuration – are very robust
components. Given appropriate sample clean-up (e.g., protein
precipitation followed by on-line SPE), quite simple maintenance of
the MS/MS analyzer is typically required only after several thousands
of samples. In this respect, LC-MS/MS systems even offer superior
robustness compared to standard clinical chemistry analyzers.
However, technical malfunctions (such as a failure of a pre-vacuum
rotary pump) sometimes cause down-times of several days, since the
response time of MS/MSmanufacturers' service centres is typically far
longer compared to the service of standard laboratory analyzers in
most regions. Consequently, for clinical LC-MS/MS applications a
back-up instrument is in most cases inevitable. Interestingly, in the
experience of most users, clearly the majority of system malfunctions
is related to the HPLC module and not to the MS/MS core unit.
The individual practice of sample preparation determines the
degree of instrument contamination. Straightforward simple protein
precipitation typically requires more frequent cleaning of the
instrument and thus down-times, while extensive sample clean-up
minimizes the need for interventions.
Protocols for a standardized assessment of the robustness of LC-
MS/MS instruments and of analyte specific assay solutions have not
been published so far. In manufacturers commercials often the peak
areas of compounds observed over hundreds of sequential injections
are shown in order to demonstrate the robustness of an instrument or
an application. More relevant, however, would be data about the
frequency of interventions needed to maintain a defined signal-to-
noise ratio for exemplary analytes in relation to the number of
samples analyzed over periods of weeks and months.
Technical optimisation of standard maintenance interventions
typically performed by the user should be a general aim for the
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cleaning of source components and to the exchange of electrospray
capillaries.
Robustness of an analytical technology does on the one hand refer
to function and down-times but on the other hand refers to analytical
reliability. LC-MS/MS-specific potential sources of inaccuracy include
interference by in-source transformation of conjugate metabolites
[54], interference by isobaric compounds [55], and bias due to
differential impact of ion-suppression or enhancement on target
analyte and internal standard [56]. Sufficient pre-fractionation and
reduction of the samples' complexity prior to analysis (involving both
sample preparation and chromatography as a functional unit) is of
essential importance to control such effects and to obtain analytical
robustness. It must be noted, however, that the degree of pre-
fractionationwhich is necessary to obtain reliable and robust results is
dependent on the individual target analyte; it is determined e.g., by
presence or absence of conjugate metabolites or isomers and by the
susceptibility to matrix effects on the ionisation using a given
individual MS/MS instrument.
Besides specific analytical issues, the reliability of results obtained
from an analytical system also depends on the robustness towards
gross handling errors. With this respect automation of the pre-
analytical part of LC-MS/MSmethods is clearly of essential importance.
All manual operations (such as labelling of secondary tubes formanual
protein precipitation, transfer of vials into a defined autosampler
position or creating a sample list) are prone to errors such as mixing-
up. It must be assumed that at present the risk of gross errors is much
higher in LC-MS/MS when compared to standard clinical chemistry
analyzer. Automation of the entire analytical process beginning with a
bar code reading of primary tubes' identification until data transfer
from the analytical system to a LIMS is evidently essential to improve
the overall robustness of LC-MS/MS methods.
Robustness towards down-times and malfunctions is as well
determined by the degree of manual actions. For example, erroneous
handling or running out of mobile phase is in our experience one of
the most frequent cause of problems and delayed reporting of results
in daily routine. A solution with pre-prepared mobile phases supplied
in mix-up proof and bar code registered containers and a liquid level
detection could avoid down-times necessary for trouble shooting.
Further improvements in the sensitivity of MS/MS analyzers may
potentially allow a further reduction of injected sample volumes thus
minimizing contamination and improving the robustness. The same
may apply for chromatographic methods with very low flow rates,
reducing contaminations due to residues in mobile phases [57].
Besides hardware components the robustness and reliability of LC-
MS/MS analyses is also determined by the commercial availability of
appropriate materials for internal standardisation, calibration, and
quality control. In particular the availability of stable isotope labelled
internal standard compounds is desirable for all LC-MS/MS applica-
tions in laboratory (which typically aim to be quantitative). The more
similar the ionisation characteristics of target analyte and internal
standard compound are, the more reliable and robust towards matrix
effects a method is [8,9]. Indeed, improper calibration and insufficient
quality control has discredited LC-MS/MS in the public perception
with respect to 25-hydroxyvitamin D quantification [58] but also to
immunosuppressant monitoring [59]. Clearly, reference materials are
as important for the robustness of LC-MS/MS methods as applies for
the current standard techniques of laboratory medicine.
Productivity and throughput
Compared to standard manual sample preparation protocols
automation of sample preparation has clearly the potential to increase
the productivity of clinical LC-MS/MS laboratory units. However,
besides sample preparation, the analytical run-time of LC-MS/MS
itself is an important limitation today. Standard run times are typicallySeite 33in a range between 3 and 8 min per sample, e.g., for immunosup-
pressants or 25-hydroxyvitamin D, corresponding to a sample
throughput of less than 20 samples per hour. This is a fraction of
the sample throughput achieved with immunoanalyzer systems (70–
200 samples/h) or clinical chemistry analyzers (N1000 samples/h).
Furthermore, changing between different LC-MS/MS assays (e.g. from
a method applying on-line SPE to a method which does not allow this
approach) is often time-consuming, includes running a new standard
series and thus further reduces the daily sample throughput. Thus,
technical solutions aiming to increase the sample throughput of LC-
MS/MS are of particular interest for laboratory medicine.
Indeed, introduction of UPLC together with latest MS/MS instru-
ments allowing a very fast acquisition of data-points over narrow
peaks now enables, e.g. the analysis of immunosuppressants within
1 min. including on-line solid phase extraction [37]. A further
interesting approach is paralleled chromatography. An autosampler
injects samples onto several analytical columns via a switching valve
in an alternating and staggered manner; only during elution of the
analyte of interest, the eluate of a respective column is directed via a
second switching valve to the MS/MS analyzer [17,60]; alternatively a
multiplexed electrospray inlet system (MUX) can analyse the eluate
of four columns simultaneously [39,61]. Such elegant solutions can
increase the throughput substantially but require much expertise.
Another way to increase the throughput of LC-MS/MS analyses is a
paralleled off-line chromatography with collection of fractions [62]. If
the fractionation achieved this way is sufficient (e.g., if conjugate
metabolites are reliably removed), flow injection of the collected
fractions from 96-position arrays without further chromatographic
separation can be performed in cycles of few seconds. Such cycle
times have been reported for MALDI-MS/MS of drugs from dried spots
without chromatographic separation [63].
Innovative and highly specific technologies of mass spectrometric
selection may potentially minimize the need for sample fractionation
prior to analysis. For example hybrid linear ion-trap instruments
enable MS3 analyses of potentially extremely high specificity.
Similarly highly mass specific detection by Fourier-transform mass
spectrometry (FT-MS) may minimize the need for time-consuming
sample preparation.
Goals for comprehensive automation
The diverse approaches to automation of LC-MS/MS analyses
discussed so far can without doubt help to improve the work of LC-
MS/MS units of clinical laboratories. However, on its own, partial
solutions e.g. of automated sample preparation do not really address
the key problem of LC-MS/MS application in laboratory medicine,
namely the limited availability of experts. Also – and in particular –
complex high-throughput automation solutions require highly skilled
staff which is increasingly a limiting resource in medicine in general.
Beyond tertiary care institutions in industrialized countries LC-MS/MS
will only become a useful new tool for laboratory medicine if indeed
full automationwill be reachedwith systems offering the same degree
of user-friendliness as applies for standard clinical analyzers today.
Such plug-and-play instruments with ready-to-use reagent kits must
be designed to be operated by ordinarily trained technicians without
the need for specialists with academic background on site. It can
reasonably be assumed that the development of such systems is
feasible for the diagnostic industry, based on the described technical
partial solutions. Such systems might be stand-alone analyzers or
even become incorporated into clinical chemistry hybrid systems.
Key specification of future plug-and-play LC-MS/MS-based clinical
analyzer systems should include the following issues:
Random-access mode (with re-calibration on demand); multi-
channel mode (assay- and sample specific selection of sample pre-
fractionation conditions from a set of generic basic methods, including
e.g., column switching); handling of standard clinical laboratory sample
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and up-load from/to a LIMS; complete and closed management of
ready-made solvents, with a reduction and minimization in the use of
toxic solvents; ready-to-use and bar code identified internal standard
mixtures; comprehensive auto-start-, auto-tuning, auto-validation and
auto-QC functions; comprehensive control of all subsystems (including
e.g., gas flows); web-based on-line technical and applicative support;
automated trouble shootingwork-flows; times-to-result of fewminutes
for individual samples; sample throughput of above 100 samples per
hour; auto-maintenance features. Implementation and down-load of
method protocols with assay-specific reagents and all instrument
settings with no need for further manual tuning or interventions, in an
open channel architecture.
Future of LC-MS/MS application in laboratory medicine
At present only rather few clinical laboratories worldwide are
equipped with LC-MS/MS systems, and in these laboratories this
technology typically makes up for less than 1% of all analyses. The
success of efforts to substantially improve the practicability and
robustness of LC-MS/MS application by automation will be crucial for
a more widespread application of this technology in the future. But is
application of LC-MS/MS in laboratorymedicine beyond the status qou
really reasonable?
Indeed LC-MS/MS can close substantial gaps in the parameter
portfolio of laboratory medicine:
- LC-MS/MS can allow routine analyses on a reference method level
of accuracy (incorporating isotope dilution technology) for
important analytes for which immunoassays offer critically limited
accuracy or cannot be applied at all (e.g., steroid hormones [64],
plasma metanephrins, 25-hydroxyvitamin D, drug of abuse
testing; methylmalonic acid, asymmetric dimethyl arginin, micro-
bial antigens).
- LC-MS/MS can allow really comprehensive therapeutic drug
monitoring (including assessment of metabolisation) for a
personalized drug therapy; this is of utmost importance in the
context of recent findings of pharmacogenetics for a large variety
of drugs. The availability of companion testing will probably also
become a key issue in the licensing of new drugs.
- LC-MS/MS enables highly multiplexed metabolic profiling which
probably holds substantial potentials for disease monitoring. LC-
MS/MS will probably be the analytical platform for all analytes
whichwill be discovered to be useful in the context ofmetabolomic
research [65].
Automation of ligand binding technologies was not less of a
challenge compared to the automation of LC-MS/MS but seemed to be
performed in a more straightforward manner. After introduction of
ELISA-plates, washers, readers, pipetting automats, soon fully auto-
mated batch-analyzers and finally random-access, multi-channel
immunoanalyzers were developed by the diagnostic industry. Now
these platforms are – besides photometry based instruments – the
cornerstone in the portfolio of in-vitro diagnostics (IVD) companies.
While essential input to the process of ligand binding assay
automation was from researchers, the driving force in the develop-
ment of routine immunoassay analyzers was obviously the IVD
industry. Such a driving force seems to be missing for the automation
in LC-MS/MS at present. Traditional IVD companies seem to avoid the
substantial investments which might ultimately seemingly result in
competition products to their own immunoanalyzers. At present,
probably less than 20% of the sales of MS/MS manufacturers are made
in the field of clinical diagnostics. Since furthermore the clinical
diagnostic market is very discerning and regulated, MS/MS manu-
facturers seem to be very reluctant towards the expensive develop-
ment of MS-based clinical analyzers as well. Consequently, it isSeite 34unclear at present if companies actually decide to make the very
substantial investments which would be required to realize such
dedicated, fully automated MS analyzers. Nonetheless, the market of
user-friendly stand-alone/front-end automation solutions for clinical
LC-MS/MS applications can be attractive for more specialized
automation companies now; also LC-MS/MS reagent kits have a
small but important market at present.
Summary and conclusions
A variety of approaches to automation of LC-MS/MS has been
described now and is increasingly used in clinical laboratories. These
approaches range from on-line SPE over sophisticated off-line robotic
systems to direct coupling of a sample preparation module to a LC-
MS/MS system. Such solutions of automation are helpful to increase
throughput, to avoid sources of gross errors, to increase the
productivity and reliability of analyses and to reduce hand-on-time
of skilled technicians. However, these solutions have not yet changed
the fact that a specialist (typically with academic background) is
required on site to implement and to run a LC-MS/MS laboratory,
which is the most critical limitation of resources for application of LC-
MS/MS in laboratory medicine. A next-level of automation has to aim
to system solutions with features of practicability which are similar to
those of today's immunoanalyzer systems and which can fully be run
by ordinarily trained technicians. Only progress towards such
solutions will make the analytical power of LC-MS/MS actually useful
for clinical medicine without limitation to specialized centres.
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